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ABSTRACT 
Aditya Bansal 
 
EFFECTS OF CHOLINE KINASE ACTIVITY ON PHOSPHOLIPID 
METABOLISM AND MALIGNANT PHENOTYPE OF PROSTATE CANCER 
CELLS 
High choline uptake and increased choline kinase activity have been 
reported in many cancers. This has motivated the use of choline as a biomarker 
for tumor imaging. Tumors in general are heterogeneous in nature with respect to 
oxygen tension. There are regions of hypoxia and normoxia that are expected to 
have different metabolism but regulation of choline metabolism under hypoxia is 
poorly understood. It is important to clarify the status of choline metabolism in 
hypoxic microenvironment as it will have an impact on potential of choline as a 
cancer biomarker. The primary goal was to determine the status of choline 
phosphorylation in hypoxic cancer cells and its effect on uptake of choline. This 
was examined by tracer studies in cancer cells exposed to hypoxia. It was 
observed that hypoxia universally inhibits choline uptake /phosphorylation in 
cancer cells. Decreased choline phosphorylation resulted in transient uptake of 
choline radiotracers in cultured cancer cells and 9L tumors suggesting potential 
problem in using choline as a biomarker for cancers in hypoxic 
microenvironment. To investigate the mechanism behind decrease in choline 
phosphorylation, steady state levels of choline metabolites were measured and 
choline kinase catalyzed choline phosphorylation step was found to be rate-
 vi 
 
limiting in PC-3 cells. This suggested that modulation in choline kinase levels can 
alter choline metabolism in hypoxic cancer cells. Expression and activity assays 
for choline kinase revealed that choline kinase expression is down-regulated in 
hypoxia. This regulation involved transcriptional level mediation by HIF1 at the 
conserved HRE7 site in choline kinase promoter. To further understand the 
importance of down-regulation of choline kinase in hypoxia, stable prostate 
cancer cell lines over-expressing choline kinase were generated. Effect of over-
expression of choline kinase in hypoxia was evaluated in terms of malignant 
phenotypes like proliferation rate, anchorage independent growth and invasion 
potential. Both over-expression of choline kinase and hypoxia had a pronounced 
effect on malignant phenotypes of prostate cancer cells. Further study showed 
that increased choline kinase activity and hypoxic tumor microenvironment are 
important for progression of early-stage, androgen-dependent LNCaP prostate 
cancer cells but confer little survival advantage in undifferentiated, androgen-
independent PC-3 prostate cancer cells. 
 
     Timothy R. DeGrado, Ph.D., Chair 
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GENERAL INTRODUCTION 
 
1. Phosphatidylcholine metabolism  
1.1. Overview of phosphatidylcholine metabolism 
Phosphatidylcholine is quantitatively the most important membrane lipid in 
eukaryotic cells (Pelech and Vance, 1984). The majority (40-60%) of the 
eukaryotic membrane phospholipids are phosphatidylcholines (Kent, 2005). The 
biosynthesis of phosphatidylcholine in eukaryotes is done by two distinct 
pathways - CDP-choline pathway (also known as Kennedy pathway) (Figure 1A) 
and successive methylation of phosphatidylethanolamine to phosphatidylcholine 
(Figure 1B). Among the two, the CDP-choline pathways represents the major 
phosphatidylcholine synthesis pathway in eukaryotes (Kent, 2005). 
1.2. Reactions of CDP-choline pathway 
The CDP-choline pathway consists of three steps: 1. phosphorylation of 
choline to form phosphocholine, catalyzed by choline kinase; 2. transfer of CMP 
from CTP to phosphocholine to form CDP-choline, catalyzed by CTP-
phosphocholine cytidylyltransferase (CCT); and 3. transfer of phosphocholine 
from CDP-choline to diacylglycerol to form phosphatidylcholine , catalyzed by 
CDP-choline: sn-1,2-diacylglycerol choline phospho-transferase (Figure 1A) 
(Kent, 2005). 
 
2 
 
 
 
3 
 
 
 
Figure 1. Biosynthesis of phosphatidylcholine in eukaryotes. (A) CDP-
choline pathway and (B) successive methylation of phosphatidylethanolamine. 
ATP = Adenosine triphosphate, CTP = Cytosine triphosphate, CCT = CTP-
phosphocholine cytidylyltransferase, CPT = CDP-choline: sn-1,2-diacylglycerol 
choline phospho- transferase, SAM = S-Adenosyl Methionine, PEMT - 
Phosphatidylethanolamine Methyltransferase. Modified from Kent, 2005. 
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1.3. Regulation of CDP-choline pathway 
1.3.1. Regulatory reactions in CDP-choline pathway 
The two regulatory enzymes in the CDP-choline pathway are choline 
kinase and CCT. Traditionally, CCT was believed to be the rate-limiting enzyme 
in phosphatidylcholine biosynthesis with choline kinase having low control 
strength in the flux in CDP-choline pathway (Ishidate, 1997). Presence of inactive 
cytosolic and active membrane bound form of CCT (Wilgram and Kennedy, 
1963), and activation of CCT by certain phospholipids (Fiscus and Schneider, 
1966) established CCT as an important regulatory enzyme for 
phosphatidylcholine synthesis. Later evidence grew to support choline kinase as 
also being rate-limiting (Infante, 1977; Infante and Kinsella, 1978) and regulatory 
in some circumstances for instance in phosphatidylcholine synthesis in mitogen 
stimulated NIH3T3 cells (Warden and Friedkin, 1985) and ras oncogene 
expressing mouse fibroblasts (Ratnam and Kent, 1995). 
1.4. Choline kinase (ChK)  
1.4.1. Overview of choline kinase  
Located in the cytoplasm, choline kinase catalyzes phosphorylation of 
choline in the presence of ATP and Mg2+ (Wittenberg and Kornberg, 1953). 
Mammalian choline kinase has 3 isoforms: ChK isoforms α1 (ChKα1); ChK 
isoforms α2 (ChKα2); and ChK isoformβ (ChKβ). ChKα1 and ChKα2 are splice 
variants with addition of 18-residue segment (RSCNKEGSEQAQNENEFQ) in the 
amino-half of the ChK α2 protein. ChK α1 is shorter than ChK α2 and is 60% 
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homology to ChKβ (Aoyama et al., 1998). The 2.7-kb gene encoding human ChK 
α is located on chromosome 11 and has 12 exons (NCBI). The 1.6-kb gene 
encoding human ChKβ is located on chromosome 22 and has 11 exons (NCBI). 
Choline kinase exists in homo- or hetero-dimeric forms (Aoyama et al., 2002). 
The proportion of the different homo- (αα or ββ) or hetero- (αβ) dimer population 
has been proposed to be tissue-specific (Aoyama et al., 2002). Furthermore, the 
combination between choline kinase isoforms results in a different level of 
choline kinase activity in vitro under cell-free systems conditions. The α/α 
homodimer is the most active choline kinase form, the β/β homodimer the less 
active, and the α/β heterodimer has an intermediate phenotype (Aoyama et al., 
2002). Distribution of isoform’s dimer population is still not known but ChKα is the 
major form of choline kinase which positively correlates with malignant 
phenotype of cancer cells (Figure 2). 
1.4.1.2. Structure of choline kinase 
Choline kinase has an N-terminal domain and a C-terminal domain, with an 
active site situated between the two domains (Figure 3) (Peisach et al., 2003). 
The N-terminal domain is composed of a five-stranded antiparallel β-sheet (β-
strands A-E) and a single α-helix (helix 1). Inserted between the third (C) and the 
fourth (D) strands of this β-sheet is an α-helix that forms the interface stabilizing 
the protein as a dimer (helix 2). Amino acids belonging to the region connecting 
the third β-strand with the interface helix are not visible in electron density maps 
of all three structures. Interestingly, this sequence segment represents the 18 
amino acids missing in α1. This insertion in hChKα2 lowers the Km for choline to 
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0.10 mM, in comparison to the much higher value of 1.69 mM for hChKα1. The 
C-terminal domain is primarily helical, and contains many of the conserved and 
functionally important residues. The loop comprising residues 302-311 is the 
Brenner’s motif, whereas the region including residues 326-354 is the choline 
kinase motif. Recently the apo structure of the nematode C. elegans choline 
kinase (CKA2), which exhibits 42% sequence identity with hChKα2, has been 
reported (Malito et al., 2006). 
  
Figure 2. Expression profile of choline kinase isoforms mRNA in various 
breast cancer cell lines. Choline kinase α isoform is upregulated in majority of 
breast cancer cell lines. Modified from Gallego-Ortega et al., 2009. The data in Y-
axis were normalized with the endogenous 18S ribosomal RNA. For the 
comparison between tumoral and non-tumoral cell line (HMEC), the 2-ΔΔCt 
method was applied and log10 RQ (relative quantity) represents Log10 of (mRNA 
signal in tumoral cells/mRNA signal in HMEC). ChKα represents both choline 
kinase alpha1 and alpha2 while ChKβ represents choline kinase beta isoform. 
 
 
 
7 
 
Comparison of the isoforms of choline kinase showed 5 conserved motifs, 
ATP-binding loop, dimer interface, link, Brenner’s motif and choline kinase motif 
(Figure 4). Out of these , Brenner’s phosphotransferase motif and putative 
choline kinase motif are reported to be part of catalytic domains (Aoyama et al., 
2004). The functions of other conserved motifs are currently unknown. Recently, 
X-ray diffraction analysis of crystallized isoform of Caenorhabditis elegans 
choline kinase (CKA2) has shown involvement of these domains in the formation 
of active dimer complex (Peisach et al., 2003). 
 
 
Figure 3. A stereo ribbon drawing of human choline kinase α dimer. α 
helices are numbered and drawn as coils, β strands are lettered and drawn as 
arrows, and other elements are drawn as tubes. ball-and-stick representation of 
ADP and PCho molecules are shown with their carbon atoms colored in orange 
and green, respectively. Oxygen, nitrogen and phosphate atoms are shown in 
red, blue and magenta, respectively. Modified from Malito et al., 2006. 
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Figure 4. Amino acid alignment of choline kinase isoforms. Alignment of 
human choline kinase isoforms (hCKα2, α1, β2), C. elegans choline kinase 
isoform alpha-2 (cCKA2), mouse choline kinase isoform alpha-1 and beta 
(mCKα1 and mCKβ), atypical enzymes - aminoglycoside 3’phospho transferase 
(APH) and cAMP-dependent protein kinase (cAPK) showing conserved ATP-
binding loop, dimer interface, link, Brenner’s motif and choline kinase motif. The 
alignment shows that atypical enzyme that show resemblance in structure do not 
share any sequence homology. Modified from Malito et al., 2006. 
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Choline kinase is known to be an enzyme primarily responsible for 
catalyzing phosphorylation of choline. No other substrate of choline kinase is 
known. Although protein phosphorylation ability of choline kinase has not yet 
confirmed but based on structure of choline it is possible that it can potentially 
phosphorylate proteins too. This is because structure of choline kinase reveals a 
typical protein kinase fold found in “atypical kinases” (AKs) family of enzymes 
(Malito et al., 2006) (Figure 5). These “atypical kinases” clearly share homology 
with the eukaryotic protein kinases (ePKs) catalytic core but do not conserve all 
of the usual kinase motifs (Figure 5).  
 
 
 
Figure 5. Comparison of structure of choline kinase, aminoglycoside 
3’phospho transferase (APH(3’)-Illa) and the catalytic domain of cAMP-
dependent protein kinase (PKA). Modified from Kent, 2005. 
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1.4.1.3. Mechanism of reaction catalyzed by choline kinase 
Kinetic mechanism of choline kinase from rat striata (Reinhardt et al., 
1984) was studied under steady state conditions using various concentrations of 
ATP- Mg2+ at several concentrations of free Mg2+ and a single concentration of 
choline (Reinhardt et al., 1984). The initial velocity, product, and dead-inhibitor 
studies with choline kinase suggested that the forward reaction follows an initial 
random ordered mechanism followed by sequential ordered mechanism (Figure 
6). ATP- Mg2+ and choline binding to the enzyme first in random order, followed 
by sequential order of activation of the ternary complex by free Mg2+. The release 
of phosphocholine occurred prior to that of ADP- Mg2+. Thus, the overall rate of 
reaction was probably limited by the release of ADP- Mg2+ from the complex 
(Ishidate and Nakazawa, 1992). 
 
 
Figure 6. Schematic diagram showing the reaction mechanism of choline 
kinase. Modified from Ishidate and Nakazawa, 1992. 
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1.4.1.4. Kinetic parameters of choline kinase 
Highly purified choline kinase preparations from different mammalian 
tissue sources have multiple Km’s (Table 1). The multiple Km’s could be 
explained either by the presence of two catalytic species (or sites) with different 
affinities for choline and ATP (Ishidate and Nakazawa, 1992; Ishidate et al., 
1985 ; Tadokoro et al., 1985) or by a mechanism of negative cooperativity 
between choline binding sites (Ishidate and Nakazawa, 1992 ; Ishidate et al., 
1985). Homogenous preparation of choline kinase from rat kidney has been 
shown to have two binding sites for choline, probably one catalytic and other 
regulatory (Ishidate et al., 1985). Choline kinase has highest activity at alkaline 
pH (8.0-9.5) as seen in in vitro assays and the activity is considerably reduced at 
neutral pH. The highest activity is obtained with an ATP/ Mg2+ ratio of 1.0 and 
excess ATP is inhibitory. Out of the two isoforms, ChKα has the ability to 
phosphorylate both choline and ethanolamine but ChKβ prefers ethanolamine for 
phosphorylation (Table 2). Ethanolamine is also phosphorylated by ethanolamine 
kinase, and phosphoethanolamine follows the CDP-ethanolamine pathway to 
form phosphatidylethanolamine. 
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Table 1. Kinetic parameters of choline kinase reaction obtained with highly 
purified or recombinant enzyme preparations. Modified from Aoyama et al., 
2004. 
 
 
 
 
Table 2. Kinetic characteristic of choline kinase isoforms, ChKα and ChKβ 
Modified from D Gallego-Ortega et al., 2009 
 
Substrate Isoform 
Equilibrium 
constant (Km) 
Standard 
error 
 
Choline 
 
ChKα 
 
0.20 
 
0.04 
 ChKβ 0.57 0.08 
 
Ethanolamine 
 
ChKα 
 
12.01 
 
2.14 
 ChKβ 2.01 0.42 
 
1.4.1.5. Choline kinase knockouts 
ChKα and ChKβ are expressed in a tissue specific manner. Recently, 
knockout studies in mice contributed to understanding of the individual role of 
isoform towards phosphatidylcholine synthesis and viability. ChKβ knockout (KO) 
mice (rmd mice) are viable, but develop a rostrocaudal muscular dystrophy, while 
Source of ChK 
Specific activity 
(mmol/min/mg) 
Equilibrium constant (Km) 
Choline(µM) ATP (mM) 
Rat kidney 3.3 100 1.5 
Rat liver 143 13 0.048 
Rat brain 40 14 1 
S. cerevisiae 128 270 0.09 
C. elegans 43 1.6 mM 2.4 
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phosphatidylcholine levels are normal in most tissues analyzed except in hind 
limb skeletal muscle (Malito et al., 2006). Therefore, ChKα is sufficient to 
maintain normal phosphatidylcholine levels in most tissues. By contrast, the lack 
of ChKα results in embryonic lethality, and ChKα+/− heterozygous mice displays 
an accumulation of choline and a reduction in phosphocholine in liver and testis, 
suggesting that there is no ChKβ compensation in ChKα knockouts for 
phosphatidylcholine biosynthesis in vivo. These results suggest different roles in 
vivo for both ChKα and ChKβ isoforms. Furthermore, the attenuated levels in 
phosphatidylethanolmine found in ChKα+/− heterozygous mice suggest the 
involvement of ChKα not only in the biosynthesis of phosphatidylcholine but also 
in the phosphatidylethanolmine pathway (Malito et al., 2006). This is also 
consistent with the fact that in ChKβ KO mice, phosphatidylethanolmine levels 
are unaffected, indicating that phosphatidylethanolmine homeostasis is fully 
maintained with the ethanolamine kinase and ChKα proteins intact. 
1.4.2. Regulation of choline kinases 
1.4.2.1. Regulation of choline kinase activity by allosteric effectors 
Yeast choline kinase is known to be allosterically regulated by ATP and 
ADP molecules in a positive cooperative manner. The positive cooperative 
kinetics exhibited by the purified choline kinase with respect to ATP is a property 
common to many nucleotide-dependent allosteric enzymes (Traut, 1994; Kim et 
al., 1998). Cooperative kinetics is generally attributed to the association of 
enzyme subunits to form oligomeric structures (Traut, 1994; Kim et al., 1998). 
Indeed, the relative amounts of the tetrameric and octomeric forms of the purified 
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yeast choline kinase increased in the presence of ATP. With respect to regulation 
by ADP, the purified choline kinase was inhibited by ADP, the product of the 
reaction. The regulation of choline kinase activity by ATP and ADP may be 
physiologically relevant. Extrapolating this to mammalian choline kinase, high Km 
for ATP and allosteric regulation by ATP and ADP allows choline kinase to 
respond to changes in energy status. 
1.4.2.2. Regulation of choline kinase activity by phosphorylation 
Phosphorylation is a major mechanism by which enzymes are regulated 
(Choi et al., 2005). Choline kinase from S. cerevisiae (yeast) is known to be 
regulated by phosphorylation (Choi et al., 2005). Choline kinase is 
phosphorylated on multiple serine residues in vivo, and some of this 
phosphorylation is mediated by protein kinase A. Protein kinase A 
phosphorylates and stimulates (∼2-fold) choline kinase at Ser30 and Ser85, with 
the former site having the major effect on enzyme regulation. Moreover, 
phosphorylation at these sites stimulates phosphatidylcholine synthesis via the 
Kennedy pathway. Recently, phosphorylation of yeast choline kinase at Ser30 
was shown to be also mediated by protein kinase C along with Ser25 (Choi et al., 
2005). In addition, S25A mutation in choline kinase decreased 
phosphatidylcholine synthesis by the Kennedy pathway due to inhibition of 
choline kinase activity. Protein kinase C is a lipid-dependent protein kinase 
required for yeast’s cell cycle and plays a role maintaining cell wall integrity (Choi 
et al., 2005). In mammalian cells protein kinase C plays a central role in the 
transduction of lipid second messengers generated by receptor-mediated 
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hydrolysis of membrane phospholipids. Phosphorylation of choline kinase by 
protein kinase in S. cerevisiae may represent a mechanism by which lipid 
signaling transduction pathways are coordinately regulated to 
phosphatidylcholine synthesis and cell growth (Figure 7). 
2. Transcriptional regulation of choline kinase 
2.1. Transcriptional factors that are involved in choline kinase expression 
2.1.1. Activator protein 1 (AP-1)  
The activator protein 1 (AP-1) is a heterodimeric transcription factor composed of 
c-Fos protein, c-Jun protein, activating transcription factor (ATF) and jun 
dimerization protein (JDP) (Hess et al., 2004). These transcription factors in the 
complex interact via their leucine-zipper domains, which in turn bring together 
their basic domains to bind DNA in a sequence-specific manner. AP-1 regulates 
transcription of genes by binding to a promoter region containing 12-O-
tetradecanoylphorbol 13-acetate (`TPA'; PMA)-responsive element (TRE; 5'-
TG/TAG/CTCA-3'). Different DNA sequence elements are preferentially 
recognized depending on the composition of the AP-1. For example, AP-1 (c-
Fos/c-Jun) binds to 5’-TGAGTCA-3’ whereas AP-1 (ATF/c-Jun) binds to 5’-
TTACCTCA-3’. AP-1 regulates gene expression in response to a variety of 
stimuli, including cytokines, growth factors, stress, and bacterial and viral 
infections. AP-1 in turn controls a number of cellular processes 
including differentiation, proliferation, and apoptosis (Florin et al., 2004).  
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Figure 7. Domain structure of yeast choline kinase: The diagram shows the 
positions of the phosphotransferase (P-transferase) and choline kinase motifs 
and protein kinase A and C (PKA and PKC) target sites in the choline kinase 
protein sequence. The numbers on the top of the diagram indicate amino acid 
positions. Modified from Choi et al., 2005. 
 
2.1.2. Hypoxia Inducible Factor (HIF-1) 
The transcriptional factor hypoxia-inducible factor 1(HIF-1) plays an 
essential role in the adaptive response of cells to reduced oxygen tension 
(Semenza, 1998). It functions as a master regulator of responses to oxygen and 
undergoes conformational changes in response to varying oxygen concentrations. 
HIF-1 consists of α and β-subunits which are both helix-loop-helix transcription 
factors (Semenza, 2000). These subunits exist as a series of isoforms encoded 
by distinct genetic loci. The β-subunit is constitutively expressed and its' activity 
is controlled in an oxygen independent manner. Expression of the α-subunit is 
induced by cellular hypoxia and is maintained at low levels in most cells in 
normal oxygen tension. The induction of HIF-1α is a critical step in 
the hypoxic response and occurs via increased mRNA expression, protein 
stabilization, and nuclear localization. The levels of HIF-1α are the primary 
17 
 
determinant of HIF-1 DNA binding and transcriptional activity. HIF1 regulates 
expression of hypoxia responsive genes by binding to hypoxia response element 
(HRE), 5’-RCGTG-3’.  
2.1.3 Sp/KLF transcription factor (SP-1) 
Transcription factor Sp1 is a zinc-finger protein that binds GC-rich 
elements (Philipsen and Suske, 1999). Its zinc fingers are of the Cys2/His2 type 
and binds the consensus sequence 5'-(G/T)GGGCGG(G/A)(G/A)(C/T)-3' (GC 
box element). GC-rich sequences are common regulatory elements in promoters 
of housekeeping genes as well as many tissue-specific genes. Sp1 has 
traditionally been considered as a constitutive transcription factor regulating 
basal promoter activity because it is expressed in all cell types and Sp1-binding 
sites are found in the promoters of many housekeeping genes. However, it is 
becoming increasingly clear that Sp1 is also involved in tissue-specific gene 
expression, its activity being finely modulated by a variety of stimuli through 
multiple posttranslational modifications (Bouwman and Philipsen, 2002). 
Transcription factor Sp1 has recently been shown to be overexpressed in a 
number of human cancers and its overexpression contributes to malignant 
transformation. Sp1 regulates the expression of a number of genes participating 
in multiple aspects of tumorigenesis such as angiogenesis, cell growth and 
apoptosis resistance.  
2.1.4. Cyclic AMP response element (CRE) -binding protein (CREB) 
One of the best characterized stimulus-induced transcription factors, cyclic 
AMP response element (CRE) -binding protein (CREB), activates transcription of 
18 
 
target genes in response to a diverse array of stimuli, including peptide 
hormones, growth factors, and neuronal activity. These stimuli activate a variety 
of protein kinases including protein kinase A (PKA), pp90 ribosomal S6 kinase 
(pp90RSK), and Ca2+/calmodulin-dependent protein kinases (CaMKs) (Shaywitz 
and Greenberg, 1999). All these kinases phosphorylates CREB at a particular 
residue, serine 133 (Ser133), and phosphorylation of Ser133 is required for 
CREB-mediated transcription response. 
2.1.5 Xenobiotic response element (XRE) binding Aryl hydrocarbon 
receptor (AhR)/Hypoxia Inducible Factor 
The Aryl hydrocarbon receptor (AhR or AHR) is a member of the family of 
basic-helix-loop-helix transcription factors. AhR is a cytosolic transcription factor 
that is normally inactive, bound to several co-chaperones. Upon ligand binding to 
chemicals such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the chaperones 
dissociate resulting in AhR translocating into the nucleus and dimerizing with 
HIF1α (also known as AhR nuclear translocator), leading to changes in gene 
transcription. The classical recognition motif of the AhR/ HIF1α complex, referred 
to as xenobiotic- responsive element (XRE), contains the core sequence 5’-
GCGTG-3’ within the consensus sequence 5’-T/GNGCGTGA/CG/CA-3’ (Lusska 
et al., 1993; Yao et al., 1992) in the promoter region of AhR responsive genes. 
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2.2. Regulatory mechanism responsible for ChKα gene expression  
2.2.1. Promoter analysis of rodent ChKα gene 
The promoter region of mouse and rat ChKα gene is highly conserved 
(Aoyama et al., 2004). In mouse liver-derived HePa-1 cells, promoter reporter 
assay identified 2 promoter regions upstream (distal and proximal) of ChKα. The 
distal promoter region of ChKα contained AP-1 binding site and xenobiotic 
response element (XRE, also known as PAH-response element), suggesting that 
in liver, exposure to CCl4 or PAH could increase expression of choline kinase 
(Figure 8). The proximal promoter of ChKα contained 3 Sp-1 site and 1 CREB 
site. This is interesting as the next enzyme of CDP-choline pathway, CCT also 
has SP-1 sites in its proximal promoter. Presence of SP-1 sites in two regulatory 
enzymes might allow coordinated regulation of CDP-choline pathway by SP-1.  
2.2.2. Promoter analysis of human ChKα gene 
Recently, a putative promoter was isolated upstream of human ChKα 
gene (Glunde et al., 2008). Like the promoter isolated upstream of rodent ChKα 
gene, human ChKα promoter had a high GC content and was TATA less. No 
core promoter region was recognized. In their study, six putative hypoxia 
response elements (5’-CGTG-3’) were identified out of which 4 closely spaced 
HREs (HRE 3-6) were shown to bind HIF1α (Figure 9). These 4 HRE sites were 
found to be associated with up-regulation of ChKα expression in promoter-
reporter assays under hypoxic condition. 
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Figure 8. Effect of CCl4 treatment on expression of choline kinase in rat liver 
(A), and (B) schematic diagram of upstream promoter of rodent choline kinase 
showing presence of AP-1 binding site in choline kinase a promoter. Modified 
from Aoyama et al., 2004. 
 
  
 
Figure 9. Schematic diagram of promoter region upstream of human 
choline kinase α gene. Figure shows putative 6 HRE sites. Modified from 
Glunde et al., 2008. 
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3. Choline transport and metabolism in normal and cancer cells 
3.1 Choline transport in normal cells 
Choline transport is required for functioning of the CDP-choline pathway. 
However, since choline is a charged hydrophilic cation, transport mechanisms 
are required for it to cross biological membranes. Three types of transport 
mechanisms have been reported based on sodium dependency, Km for choline 
and Ki for hemicholinium (specific inhibitor of choline transport) (Lockman and 
Allen, 2002). Transport mechanisms include: 1. Sodium-dependent high-affinity 
uptake mechanism (Lockman and Allen, 2002) found in synaptosomes (choline 
Km < 10 µM ; hemicholinium Ki ~ 0.001-0.1 µM); 2. Sodium- independent low-
affinity uptake mechanism (Lockman and Allen, 2002) found ubiquitously in all 
cells (choline Km > 30 µM ; hemicholinium Ki ~ 100 µM); and 3. A unique choline 
uptake mechanism found in blood-brain barrier choline transport that has affinity 
for choline similar to high affinity mechanism but sodium independence, and 
hemicholinium Ki similar to low affinity mechanism (Lockman and Allen, 2002).  
3.2. Choline transport in cancer cell lines and cancerous tissues 
Elevated choline tracer levels seen in the tumors have been postulated to 
be dependent on high choline kinase activity seen in tumors (Katz-Brull and 
Degani, 1996; DeGrado et al., 2001; Hara et al., 2002; Katz-Brull et al., 2002). 
However, elevated choline tracer levels in tissues would also require increased 
transport of choline. A non-metabolizable [18F]fluorinated choline analog, 
deshydroxy- [18F]fluorocholine ([18F]dOC) was used by Henrikson et al. to 
address choline transport in cancer cells (Henriksen et al., 2004). Concentration-
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dependent inhibition of membrane transport of both compounds by similar 
concentration of cold choline showed involvement of choline specific transport 
system in transporting [18F]dOC into cultured rat pancreatic carcinoma (AR42J) 
cells (Henriksen et al., 2004). Uptake of [18F]dOC was compared with that of 
[11C]choline in cultured rat pancreatic carcinoma (AR42J) and PC-3 human 
prostate cancer cells at different time points. In the study, the fraction of [18F]dOC 
in PC-3 and AR42J cells after 5 min incubation time was comparable to that of 
[11C]choline, whereas the uptake of [11C]choline was more after 20 min 
incubation time as compared to [18F]dOC . The results from the experiments with 
cultured cell lines showed that, at early time points after incubation (5 min), 
transport seems to be the limiting factor with minimum effect of phosphorylation 
(Henriksen et al., 2004). At late time points (20 min), phosphorylation was 
important for retention of choline. Uptake of radiolabeled choline at the time 
relevant for oncological PET (Positron Emission Tomography) is likely dominated 
by choline transport although dual time PET is dependent also on choline kinase 
activity via metabolic trapping (Henriksen et al., 2004). In dual time PET, choline 
retention is measured at two time points. Increased choline retention with time is 
primarily due to preferential uptake and phosphorylation of choline in tumor as 
compared to normal cells.  
 Choline transport in cancer cells is at present not well understood due to 
limited data on choline transporter in cancer cells. The identity of the transporter 
for choline in cancer cells is unknown, although recent work (Martel et al., 2001) 
has identified two sodium independent 1-methyl-4-phenylpyridinium (MPP+) 
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transporters in colon adenocarcinoma cells. These transporters belong to the 
amphiphilic solute facilitator (ASF) family that include recently identified (and 
cloned) choline transporter hOCT1 (Burckhardt and Wolff, 2000) and hOCT3 
(Burckhardt and Wolff, 2000) in kidney and liver. Saturation kinetics and 
substrate specificity of choline transport in many cancer cell line have shown 
similarity to organic cation transporters (OCTs) reported in kidney and liver. In 
future, identification, cloning and characterization of choline transporters in 
cancer cells will lead to better understanding of their role in carcinogenesis. 
3.3 Choline metabolism 
Choline, after entering the cell, can either be oxidized to betaine by 
mitochondrial enzymes mostly seen in liver or kidney or converted to 
phosphocholine by cytosolic choline kinase. Metabolites of choline have different 
roles. In liver, betaine is an important donor of methyl group to homocysteine for 
the formation of methionine (Finkelstein et al., 1982). In kidney, betaine serves as 
an osmolyte (Garcia-Perez and Burg, 1991).The major pathway of choline 
incorporation into phosphatidylcholine in mammalian cells (other than liver and 
kidney) is via CDP-choline pathway. Choline can also be retained in the cells in 
free choline form as seen in human mammary epithelial cells (HMECs) (Katz-
Brull et al., 2002).  
Choline kinase is known to be overexpressed in lung, colorectal and 
prostate cancers (Ramirez de Molina et al., 2002) and in human mammary 
carcinomas (Ramirez de Molina et al., 2002). Most of the choline in MCF7 cells 
(breast cancer cell line) was converted to phosphocholine and then routed 
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through the CDP-choline pathway to form choline phospholipids. A significant 
amount of choline ( 25%) was oxidized to betaine, and most of betaine was 
found in the growth medium of the cells. It therefore appears that the two 
pathways, phosphorylation and oxidation of choline, are both augmented in the 
course of malignant transformation of mammary cells (Katz-Brull et al., 2002). 
4. Choline kinase as an oncogene 
4.1. Choline kinase and cell signaling 
It has been shown that phosphocholine confers mitogenic properties to 
mouse fibroblasts upon stimulation by PDGF or FGF (Cuadrado et al., 1993; 
Jimenez et al., 1995). A full understanding of how choline kinase and its 
downstream substrates contribute to tumorigensis has yet to be disclosed, 
although some previous studies clearly correlate choline kinase regulation with 
Rho A signaling, and transcriptome analysis of choline kinase overexpression 
demonstrates its effects on cell cycle regulation and apoptosis impairment 
(Rodriguez-Gonzalez et al., 2004; Ramirez de Molina et al., 2005; Ramirez de 
Molina et al., 2008). Recently, using a human siRNA library, various kinases 
were silenced in MDA-MB 468 breast cancer cells to screen for candidate 
kinases that regulate Akt phosphorylation (Chua et al., 2009). In the study, ~ 12% 
of the human kinome could directly or indirectly regulate Akt(ser473) 
phosphorylation. Silencing of ChKα reduced Akt(ser473) phosphorylation 
significantly, suggesting the potential role of ChKα as a regulator of Akt pathways. 
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4.2. Choline as a cancer biomarker 
4.2.1. Choline based Positron Emission Tomography (PET) imaging of 
malignant cancers  
High choline uptake and increased choline kinase activity have been 
reported in many cancers (Katz-Brull and Degani, 1996; DeGrado et al., 2001; 
Hara et al., 2002; Katz-Brull et al., 2002). Choline kinase is known to be over-
expressed in lung, colorectal, and prostate cancers (Ramirez de Molina et al., 
2002). The potential for PET imaging using [11C]choline has been shown in 
detection of brain tumor (Hara et al., 1997; Shinoura et al., 1997), prostate 
carcinoma (Hara et al., 1998), and esophageal carcinoma (Hara, 1987). However, 
the short half-life of [11C]choline (T1/2 = 20 min) limits its use to facilities that have 
a cyclotron within a short distance from the imaging suite. To allow for more 
practical distribution of a longer-lived tracer, the 18F-labeled choline analog (T1/2 = 
109 min), [18F]fluorocholine ([18F]FCH) was developed (DeGrado et al., 2001; 
DeGrado et al., 2001). Preliminary studies have shown [18F]FCH to be a 
promising PET imaging tracer for prostate cancer, hepatocellular carcinoma and 
brain tumor imaging (Coleman et al., 2000; DeGrado et al., 2001; Hara, 2001; 
Price et al., 2002; Kwee et al., 2004; Kwee et al., 2005; Schmid et al., 2005; 
Cimitan et al., 2006; Heinisch et al., 2006; Kwee et al., 2006; Talbot et al., 2006) . 
4.2.2. Choline based Magnetic Resonance Spectrometry Imaging (MRSI) of 
malignant cancers  
High resolution 1HMR spectroscopy (MRS) of tissue and cell extracts can 
resolve individual choline phospholipid metabolites and can be used to quantify 
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phosphocholine (PC), glycerophosphocholine (GPC), and free choline 
(Cho)(Ackerstaff et al., 2003). With 1H-MRS of intact cells or solid tumors, an 
unresolved signal of overlapping PC, GPC, and free choline resonances, referred 
to as total choline containing metabolites (tCho) is observed. The elevation of the 
tCho signal detected in preclinical and clinical 1H magnetic resonance 
spectroscopy (MRS) and MRS imaging (MRSI) studies (Glunde et al., 2008) is 
often observed to be associated with malignancy and high rate of angiogenesis. 
In prostate cancer, this tCho signal, combined with the citrate signal, has been 
shown to correlate with staging of the disease by the Gleason score and has 
shown promise in clinical 1H MRSI studies of prostate cancer to noninvasively 
evaluate prostate cancer aggressiveness (Glunde et al., 2008). 
 5. Specific aims and hypotheses 
 The goals for this thesis were: (a) to confirm if hypoxia mediated decrease 
in choline phosphorylation and choline kinase activity is a universal response in 
cancer cells, (b) to understand the mechanism behind inhibition of choline 
phosphorylation in hypoxic cells and (c) to understand the effect of hypoxia and 
increased choline kinase activity on malignant phenotype of cancer cells. 
Three hypotheses were examined in this study: 
 
Hypothesis 1: Choline phosphorylation and retention is decreased in hypoxic 
cancer cells and hypoxic tumor xenograft model.  
Aim 1: Evaluate fate of choline in hypoxic cancer cells and in subcutaneous 9L 
glioma tumor xenograft model. 
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Hypothesis 2: Decreased choline phosphorylation in hypoxic prostate cancer 
cells is due to HIF1 mediated transcriptional control of ChKα. 
Aim 2a: Evaluate ChKα.and HIF1α. expression in cancer cells exposed to 
normoxia (21% O2) and hypoxia (1% O2) for 24h and 48h.  
Aim 2b: Determine whether modulation of choline uptake and choline kinase 
activity is a HIF1α dependent response. 
Aim 3b: Characterize the ChKα promoter associated with HIF1α mediated 
regulation of ChKα expression. 
 
Hypothesis 3: Hypoxia and over-expression of choline kinase influences 
malignant phenotypes of prostate cancer cells representing different stages of 
disease progression. 
Aim 3: Evaluate affects of hypoxia and over-expression of choline kinase on 
proliferation, migration, invasion and colony formation of non-invasive LNCaP 
cells and highly invasive PC-3 cells. 
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CHAPTER I 
 
Choline phosphorylation and retention is decreased in hypoxic cancer cells 
and the hypoxic tumor xenograft model  
1. Abstract  
The choline kinase enzyme is frequently over-expressed in malignancy. 
Therefore, choline, which is a substrate for choline kinase, has the potential to 
serve as oncologic probe for imaging cancers. Effect of hypoxia on choline 
uptake and metabolism in cancer cells was examined as a test of the hypothesis 
that tumor oxygenation should be considered when choline based imaging 
studies are used to noninvasively detect malignant cells. This hypothesis was 
tested by exposing cancer cells to low oxygen environment (1% O2) for 24h. 
Hypoxia had a negative impact on choline uptake and phosphorylation in rat 9L 
glioma cells, human PC-3 and LNCaP prostate cancer cells. To further test this 
response in in vivo model, choline uptake and metabolism was examined in 
hypoxic subcutaneous 9L tumor. Uptake of choline was transient in the hypoxic 
9L tumor and the majority of radiolabel in tumor, like in hypoxic cultured 9L cells, 
was found as nonmetabolized choline. Previously, [18F]Fluorocholine (FCH) has 
been developed as an analog of choline for tumor imaging. Regional FCH 
deposition and tumor perfusion study with the 9L glioma tumors showed that 
FCH uptake spatial pattern followed closely with the intratumoral distribution of 
perfusion. No significant change was seen with time in average blood flow in 
these hypoxic 9L tumors but there was a significant decrease in average FCH 
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retention from 5 min to 20 min. The study suggests that the heterogeneity of 
tumor uptake of choline analogs depends largely on the heterogeneity of 
perfusion/oxygenation and should be carefully considered in interpreting choline 
based imaging. 
2. Introduction 
In recent years, choline metabolites have been widely studied in cancer 
research. High choline uptake and increased choline kinase activity have been 
reported in lung, breast, colorectal, and prostate cancers (DeGrado et al., 2001; 
Katz-Brull et al., 2002; Ramirez de Molina et al., 2002). This alteration in choline 
metabolism in neoplasm relative to normal tissues has motivated evaluation of 
proton magnetic resonance spectroscopic imaging (MRSI) of total choline pool 
size (Jacobs et al., 2004; Katz-Brull et al., 2002) and positron emission 
tomography (PET) imaging of choline uptake (DeGrado et al., 2001; Shinoura et 
al., 1997) as cancer imaging techniques for diagnosis and therapy monitoring. 
 Although overall choline uptake in tumors is high, intra-tumoral uptake 
pattern regions can exhibit considerable heterogeneity (Jacobs et al., 2004; 
Schmid et al., 2005). Multiple factors may be involved, such as heterogeneity of 
tumor perfusion, oxygenation (hypoxia) and extracellular pH. Such factors are 
known to regulate biochemical and physiological processes within tumor 
cells (Kallinowski et al., 1989) but their effects on choline metabolism are not well 
understood. Tracer studies with mouse atrial cardiomyocyte tumor lineage, AT-1 
(Sarri et al., 2006) showed that hypoxic exposure reduces choline 
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uptake/phosphorylation (Figure 10). Reduced tracer uptake was accompanied by 
reduced choline kinase activity.  
 
Figure 10. Hypoxia inhibits phosphorylation of choline and formation of 
CDP-choline in atrial cardiomyocytes. Modified from Sarri et al., 2006. 
 
This effect of hypoxia on choline uptake/metabolism was not limited to 
cancer cells derived from rodents but also seen in human cancer cell lines. In our 
previously reported study, with two human prostate cancer cell lines after 4h of 
anoxia (0% O2), PC-3 cells showed 15% decrease in choline uptake, whereas 
LNCaP cells showed 28% decrease in choline uptake (Figure 11) (Hara et al., 
2006). After 24h of anoxia, choline uptake and cell proliferation rate continued to 
decrease in both cell lines with no change in cell viability. The purpose of this 
study was to evaluate the effect of chronic hypoxia (1% O2) on choline uptake 
and metabolism in cancer cells. 
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Figure 11. Uptake of [3H]choline, [14C]acetate and [18F]FDG in prostate 
cancer  cells: (A) and LNCaP cells (B) in normal-serum-supplemented medium. 
The 30-min uptake was measured after 0, 4 and 24 h of anoxic incubation, 
without interrupting anoxia. Error bars indicate standard deviations (n = 5). 
Modified from Hara et al., 2006. 
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3. Materials and Methods  
3.1. Material chart 
ATCC, Manassas, VA 
9L glioma cells 
PC-3 and LNCaP prostate cancer 
cells 
RPMI-1640 medium 
PBS 
Fetal bovine serum  
0.25% Trypsin-EDTA 
Charles River Laboratoires, 
Wilmington, MA 
Male Fisher CDF 344 rats 
Perkin Elmer, Waltham, MA Solvable 
Eppendorf, Westbury, NY Centrifuge 5415R 
Sigma, St. Louis, MO 
Sodium Pentobarbital, Streptomycin, 
NaOH, SDS, RIPA lysis buffer, protease 
inhibitor cocktail, DMOG, chloroform, 
methanol, urea, sulfiuric acid, acetonitrile, 
ammonium acetate, penicillin, scintillation 
cocktail, glacial acetic acid, HEPES , 
Triton X-100, EDTA, Bovine Adult Serum, 
N-tosyl-Lphenylalanine chloromethyl 
ketone (TPCK), trypsin inhibitor, 
leupeptin, DTT, PMSF), Tris, HCl, ATP, 
MgCl2, choline 
Grace (Alltech), Deerfield, IL HPLC column, column heater 
Varian, Palo Alto, CA Mass-spectrometer 
Research Products International 
Corp., Prospect, IL 
Polytron homogenizer 
Waters, Milford, MA HPLC system 
Ruskinn Technologies, 
Bridgend, UK 
Invivo work station 
GE Healthcare (Amersham 
Biosciences), Piscataway, NJ  
[14C]choline, [14C]iodoantipyrine (IAP) and 
[3H]choline 
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3.2. Tumor xenograft model 
Male Fisher CDF 344 rats (~ 200 g) were anesthetized with sodium 
pentobarbital (45 mg/kg IP). The thigh area was shaved and 2-3 x 106 cultured 
9L glioma cells suspended in 50 μl PBS were inoculated under the skin. The 
tumor was allowed to grow to the size of approximately 1.5 cm3 (about 4 weeks). 
3.3. Establishment of hypoxic environment 
Cells were cultured in high glucose (4.5g/L) RPMI-1640 medium (ATCC) 
or DMEM (ATCC) supplemented with 10% (v/v) fetal bovine serum (ATCC), 100 
units/ml penicillin (SIGMA), and 0.1 mg/ml streptomycin (SIGMA). Cells were 
grown at 37°C in a humidified CO2 incubator. For hypoxic conditions, cells in 
medium were exposed to 1% O2 balanced with 5% CO2/94% N2 in a hypoxia 
work station (In vivo2 300, Ruskinn Technologies, Bridgend, UK) for 24h. For 
chromatin immunoprecipitation (ChIP) assays and promoter-luciferase assays, 
hypoxic conditions were induced by exposing cells to 2mM 
dimethyloxaloylglycine (DMOG) for 24h. DMOG stabilizes HIF1α and acts as a 
hypoxia mimetic. 
3.4. Uptake of radiolabeled choline in cancer cells 
Studies of tracer choline uptake were performed in cultured cancer cells in 
normoxic and hypoxic conditions. For the latter condition, a 24 h exposure to 
hypoxia (1% O2) was chosen as a preconditioning period before administration of 
choline radiotracers because significant changes in protein expression are seen 
only during prolonged (>16 h) hypoxic (1% O2) exposure (Liu et al., 2006). 
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Furthermore, in our experience, cancer cells are viable under hypoxia (1% O2) for 
48 h (Hara et al., 2006). Sub-confluent cultures of cancer cells were placed under 
a humidified normoxic gas mixture (21% O2, 75% N2, 5% CO2) or a hypoxic gas 
mixture (1% O2, 94% N2, 5% CO2). After 24h incubation at 37°C, the cells were 
then incubated with radiolabeled choline for different time points. At the end of 
incubation, the cells were washed 3 times with chilled phosphate buffered saline 
(PBS). Exposure to respective gas mixture was maintained throughout the 
experiment. Uptake studies were done in cell medium supplemented with 10% 
fetal bovine serum in triplicate in 6 well plates. The medium contained 28 μM 
choline (physiological range 10-30 μM, ~ 74 KBq radiolabeled choline per well. 
After incubation with the radiotracers, the cells were lysed in 1 ml of 0.3 N NaOH 
and 1% SDS. Scintillation fluid was added to the samples and they were counted 
for 14C-radioactivity using a liquid scintillation counter. For metabolite analysis, 
the cells were incubated with ~ 444 KBq radiolabeled choline per well.  
3.5. Pulse chase experiment  
To investigate the efflux rates of radioactivity from cancer cells a pulse 
chase experiment was performed. After 24 h incubation at 37°C under normoxic 
or hypoxic conditions, the cancer cells were incubated with radiolabeled choline 
for 2 h at 37°C under similar conditions. The cells were then washed with PBS 
and incubated in fresh medium. The cycle of washing and incubation was 
repeated every 15 min over a 2 h period. Radioactivity was counted in the PBS 
washes and the incubation medium after each cycle. The PBS washes and the 
fresh medium were equilibrated with 21% O2 (normoxic condition) or 1% O2 
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(hypoxic condition). Hydrophilic choline metabolites in the washout were 
analyzed using HPLC. 
3.6. Measurement of choline metabolite levels in cells 
For metabolite analysis, the cells were scraped in 500 μl 
chloroform/methanol (2:1) and sonicated at 4°C. To the sonicated cell 
suspension was added 100 μl aqueous urea (40%) and 100 μl sulfuric acid (5%). 
The cells were sonicated for another 15 s, and then centrifuged at 2,500 g for 5 
min at 4°C. Hydrophilic choline metabolites in the aqueous layer were analyzed 
using gradient HPLC as described below. Aqueous and organic fractions were 
separated and counted. 
3.7. Uptake of radiolabeled choline in tumor xenograft 
Groups of animals (n = 4 each) were studied after bolus intravenous 
administration of [14C]choline (1.8 MBq) and [18F]FCH (5 MBq) in isotonic saline. 
At 5 or 20 min after bolus injection, rats were euthanized and blood 
samples/tumor tissues/skeletal muscle was excised for radioactivity counting and 
metabolite analysis. Tumor and skeletal muscle tissue samples were rinsed in 
chilled saline and blotted to remove excess liquid. A portion of each tissue was 
weighed and counted for radioactivity, while the remainder was used for 
metabolite analysis. For calculating uptake of tracers, 18F radioactivity was 
counted immediately. For 14C-radioactivity, 18F-radioactivity was allowed to decay 
while tumor tissue or muscles are incubated with 0.5 ml tissue solubilizer 
(SOLVABLE, Perkin Elmer) at 37°C overnight, 5 ml scintillation cocktail was 
added, and 14C-radioactivity was counted. 
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3.8. Analysis of radiolabeled choline metabolites in cancer cells and tumor 
tissue 
Tissue samples were homogenized using a polytron homogenizer in 5 ml 
chloroform/methanol (2:1) at 4°C. The homogenate was sonicated for 15 s, then 
1 ml aqueous urea (40%) and 1 ml sulfuric acid (5%) was added. The 
suspension was sonicated for another 15 s. The suspension was centrifuged at 
2,500 g for 5 min. Aqueous and organic fractions were separated and counted. 
Plasma samples were worked up as described above for tissue without 
homogenization. Samples of the aqueous phase were applied to an 
Adsorbosphere Silica HPLC column (4.6 x 250 mm, 10 μ) (Alltech Associates, 
Deerfield, IL). The following gradient was used for the HPLC separation: Solvent 
B in the eluent: 0% at 0-3 min, 0-30% at 3-10 min, 30-40% at 10-20 min, 40-
100% at 20-22 min, 100% at 22-50 min, 100-0% 50-56 min, and 0% at 56-57 min. 
Solvent A was acetonitrile/water/ethanol/ 1M ammonium acetate/glacial acetic 
acid (0.8/0.127/0.068/0.003/0.002 (v/v)) and Solvent B was 
Acetonitrile/water/ethanol/1M ammonium acetate/glacial acetic acid 
(0.44/0.44/0.085/0.027/0.018 (v/v)). The HPLC eluant was collected in 1-min 
fractions. Based on their retention time, the metabolites phosphocholine (31 min), 
phosphoryl-[18F]FCH (28 min), choline (16 min), betaine (11 min), [18F]FCH (13 
min) and [18F]fluorobetaine (8 min) were identified in the fractions. Retention 
times were determined using unlabeled standards of choline, FCH, betaine, 
fluorobetaine, phosphocholine and phosphoryl-FCH and mass-spectrometry 
detection (Varian, Palo Alto, CA). 18F-radioactivity in 100 μl standard of injectate 
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and collected samples were measured in gamma counter. The samples were 
then allowed to decay for at least 24 h. The injectate and samples in a liquid 
scintillation counter were counted for 14C-radioactivity. 
3.9. Measurement of choline kinase activity in cancer cells and tumor 
tissue 
The cells were scraped and homogenized in chilled extraction buffer pH 
7.5 (30 mM HEPES pH 7.5, 3% Triton X-100, 2 mM EDTA, 2% Adult Bovine 
Serum, 10 μM N-tosyl-Lphenylalanine chloromethyl ketone (TPCK), 10 mg/ml 
trypsin inhibitor, 1 μM leupeptin, 0.75 mg/ml DTT, 0.4 mg/ml PMSF). The cell 
homogenate was centrifuged for 10,000 g for 20 min at 4°C. The supernatant 
was used for the assay as described by (Ishidate and Nakazawa, 1992) . The 
assay mixture (300 μl) contained 0.1 M Tris-HCl, pH 7.5, 10 mM ATP, 12 mM 
MgCl2, 100 μM choline, [
14C]choline (~ 0.7 MBq / assay mixture). Samples were 
incubated at 37°C for 30 min. 
3.10. Tumor perfusion assay and spatial localization of radiolabeled choline 
in tumor xenograft  
Regional FCH deposition and tumor perfusion were compared at sub 
millimeter spatial resolution by 2-D autoradiography of 18F/14C following 
administration of FCH and the perfusion marker, [14C]iodoantipyrine (IAP). 
Tumors were excised, frozen at 5 min and 20 min after bolus administration of 
FCH. Intravenous infusion of IAP began 1 min prior to termination of experiment. 
The frozen tumor was sliced at 10 micron thickness. Quantitative maps of 
regional perfusion and FCH retention were obtained. 
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3.11. Statistical analysis 
Results are presented as means ± standard deviation. Student’s t-test was 
applied for statistical evaluation and a p-value <0.05 was considered significant. 
4. Results  
4.1. Hypoxia decreased choline uptake and phosphorylation in cancer cells 
In normoxic cancer cells incubated with radiolabeled choline, the choline 
tracers were taken up avidly, and rapidly phosphorylated. The uptake of choline 
increased in a linear fashion with increasing incubation time in normoxic cancer 
cells (Figure 12-13). The aqueous soluble radioactivity was nearly completely 
(>95%) in the form of phosphocholine at incubation periods as short as 5 min. At 
120 min, 99% of the radioactivity is contributed by phosphorylated form. The 
pattern of choline uptake and phosphorylation was different in hypoxia depending 
on the cancer cell. In hypoxic condition, majority of fraction at early time points 
<20min , was dominated by non-metabolized choline. At 120 min, following 
exposure to chronic hypoxia, two responses were seen. In one set of cancer cells 
(PC-3, prostate cancer cells), there was a significant difference in choline uptake 
at 120 min of incubation primarily due to strong inhibition of choline 
phosphorylation (Figure 12). At 120 min, most of the radioactivity (98%) in these 
cells is contributed by non-metabolized choline with <2% in phosphocholine form. 
In the second set of cancer cells (9L glioma cells and LNCaP, prostate cancer), 
choline phosphorylation was decreased in hypoxia but not to the extent seen in 
PC-3 and ovarian cancer cells. This slight but significant decrease in choline 
phosphorylation caused a modest decrease in choline retention at 120 min of 
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incubation (Figure 13). The major proportion (95%) of the radioactivity in these 
cells is contributed by phosphorylated form at 120 min incubation. 
To further investigate the fate of radiolabeled choline metabolites, a pulse-
chase experiment was performed. Two cell lines were chosen representing the 
two uptake/phosphorylation responses to hypoxia. For strong choline 
phosphorylation inhibition response, PC-3 cells were used and for the modest 
choline phosphorylation inhibition 9L glioma cells were used. After administering 
a pulse of radiolabeled choline tracers for 120 min in normoxic condition, 
moderate levels of radioactivity were washed out of PC-3 and 9L glioma cells in 
successive 15 min incubations (Figures 14 and 15). In PC-3 cells, the washout 
rate was significantly higher in hypoxia as compared to normoxia (Figure 14). 
While in case of 9L glioma cells, the difference between washout rates in hypoxia 
was significantly higher than seen for normoxic cells (Figure 15). 
4.2. Hypoxia increased choline/phosphocholine ratio in cancer cells 
To further confirm the significant decrease in choline phosphorylation in 
PC-3 cells, steady state levels of choline metabolites were measured. In the 
normoxic state, PC-3 cells had 0.031 ± 0.012 µmol choline /200mg protein and 
2.1 ± 0.2 µmol phospho-choline /200mg protein. Marked changes in 
concentrations of these metabolites were seen in the hypoxic state. Hypoxia 
caused a ~ 666% increase in concentration of choline and 14% decrease of 
phosphocholine (Table 2). Consistent with the decreased choline 
phosphorylation, a 30% decrease in choline kinase activity was observed in 
hypoxic cells (Table 2). Hypoxia also decreased the energy state of PC-3 cells as 
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evidenced by ~ 19% reduction in concentration of ATP. The 
phosphocholine/choline ratio was decreased by 10 fold in hypoxic cells 
(phosphocholine/choline = 7.8) as compared to normoxic cells 
(phosphocholine/choline = 70) (Table 3). The MAR/Keq of choline 
phosphorylation in PC-3 was 19 X 10-4 based on published Keq value = 1.24 X 
104 (Infante, 1977, Infante et al., 1978). 
 
Table 3. Choline kinase (ChK) activity and metabolite levels in prostate 
cancer cell extracts in serum-supplemented medium after 24 h normoxia 
(1% O2) and hypoxia (21% O2) (n = 3, each condition). ChK activity is 
expressed as nmol choline phosphorylated/min/mg protein.*p<0.05 s values in 
normoxia using unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell line 
 
ChK activity 
 
Choline 
mM 
Phosphocholine 
mM 
ATP 
mM 
PC-3 Normoxia 2.43 ± 0.02 0.031 ± 0.012 2.1 ± 0.2 3.2 ± 0.2 
PC-3 Hypoxia 1.7 ± 0.1* 0.23 ± 0.06* 1.8 ± 0.1* 2.6 ± 0.1* 
LNCaP Normoxia 1.22 ± 0.04 0.031 ± 0.01 2.7 ± 0.1 4.4 ± 0.3 
LNCaP Hypoxia 0.85 ± 0.1* 0.08 ± 0.02* 2.4 ± 0.1* 3.8 ± 0.2* 
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Figure 12. Uptake of radiolabeled choline in PC-3 prostate cancer cells. 
Uptake is shown as function of oxygenation status and incubation period. Values 
are shown as % administered dose per 106 cells (mean, n = 3). * p < 0.05 Vs 
values in normoxia using unpaired t-test. 
 
 
Figure 13. Uptake of radiolabeled choline in LNCaP prostate cancer cells: 
Uptake is shown as function of oxygenation status and incubation period. Values 
are shown as % administered dose per 106 cells (mean, n = 3). * p < 0.05 Vs 
values in normoxia using unpaired t-test. 
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Figure 14. Efflux of choline radioactivity from normoxic and hypoxic PC-3 
cells: Representative graph showing efflux of trapped choline radioactivity upon 
successive washing after incubating the cells for 2 h with [14C]choline under 
normoxic (21% O2) and hypoxic (1% O2) condition.  
 
 
Figure 15. Efflux of choline radioactivity from normoxic and hypoxic 9L 
glioma cells: Representative graph showing efflux of trapped choline 
radioactivity upon successive washing after incubating the cells for 2 h with 
[14C]choline under normoxic (21% O2) and hypoxic (1% O2) condition.  
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4.3. Uptake of radiolabeled choline in hypoxic subcutaneous tumor is 
transient  
To understand the effect of hypoxia mediated inhibition of choline 
phosphorylation on choline uptake in animal tumor models, choline tracer studies 
were performed in hypoxic 9L glioma tumor model. In 9L tumor, hydrophilic 
metabolites dominated the fate of both [14C]choline and [18F]FCH, with 98% of 
radiolabel found in the aqueous phase at both 5min and 20min post-injection. 
Tumor: muscle and tumor: blood ratio decreased from 5 min to 20 min for both 
[14C]choline and [18F]FCH (Table 4). HPLC analysis of extracts of tumor showed 
major amount of radioactivity contributed by nonmetabolized [14C]choline and 
[18F]FCH. The fraction of nonmetabolized [18F]FCH and [14C]choline in tumor 
decreased from 5 min to 20 min. The fraction of radioactivity in the form of 
[14C]betaine and [18F]fluorobetaine was significantly small. 
 
Table 4. Tumor- to-background ratio of [14C]choline and [18F]FCH in 9L-
glioma bearing Fisher rat. Values are mean ± standard deviation (n = 4) 
 
 Time post-
injection (min) 
14C 18F 
Tumor : blood 5 4.22 ± 0.84 2.55 ± 0.66 
 20 1.46 ± 1* 0.88 ± 0.58* 
Tumor: muscle 5 5.85 ± 0.94* 6.27 ± 0.81 
 20 1.05 ± 0.69* 1.05 ± 0.59* 
*p< 0.05 Vs value at 5 min using unpaired t-test. 
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4.4. Choline uptake pattern coincides with blood flow pattern of the tumor 
xenograft 
[18F]FCH uptake pattern followed closely the intra-tumoral distribution of 
blood flow. The tumor had a necrotic center with no blood flow. The blood flow 
was restricted to the periphery of the tumor which coincided with the region that 
had appreciable [18F]FCH retention (Figure 16). Transient uptake of [18F]FCH in 
9L tumor was confirmed evident from decrease in [18F]FCH retention in the 9L 
tumor with time independent of blood flow (Table 5). 
 
 
Figure 16. Representative autoradiograph of sections of 9L glioma tumors. 
[18F]FCH retention correlated with blood flow marker [14C]Iodoantipyrine at 5min 
and 20 min post-injection. 
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Table 5. Blood flow and FCH retention estimates of 9L glioma tumors at      
5 min (n = 4) and 20 min (n = 4) post-injection.  
 
Time post-
injection 
(min) 
Maximum 
blood flow 
(ml/g.min) 
Average blood 
flow (ml/g.min) 
Maximum FCH 
retention (% 
dose/g) 
Average FCH 
retention (% 
dose/g) 
5 0.17 ± 0.04 0.07 ± 0.028 3.27 ± 0.62 1.99 ± 0.32 
20 0.11 ± 0.10 0.04 ± 0.032 2.14 ± 0.21* 1.102 ± 0.39* 
*p< 0.05 Vs value at 5 min using unpaired t-test. 
5. Discussion  
Hypoxia decreased uptake of choline in all cancer cells studied. In some 
cells, the decrease was more pronounced than in others. In PC-3 cells, due to 
strong inhibition of choline phosphorylation, choline tracer accumulation was 
completely abrogated in hypoxic conditions for incubation periods greater than 20 
min, whereas normoxic cells accumulated radiolabeled choline throughout a 2 h 
incubation period. Furthermore, the smaller amount of radiolabeled choline that 
was taken up by hypoxic PC-3 cells was quickly washed out when the medium 
did not contain radiotracer in the pulse chase experiment. In contrast, nearly all 
the radioactivity was retained within normoxic PC-3 cells in the form of 
radiolabeled phosphocholine. In 9L glioma cells, due to modest inhibition of 
choline phosphorylation, hypoxic 9L glioma cells were able to accumulate choline 
tracer with slower rate than seen in normoxic conditions. Due to slow choline 
phosphorylation, only modest levels of radioactivity were washed out of hypoxic 
9L glioma cells as compared to normoxic cells. This washout rate was 
significantly less than that seen for hypoxic PC-3 cells. 
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The reason for the strong hypoxia-induced inhibition of choline uptake/ 
phosphorylation in PC-3 cells and ovarian cancer cells as compared to 9L glioma 
cells, LNCaP cells and pancreatic cancer cells is not clear. In both PC-3 and 9L 
glioma cells, choline kinase activity was decreased by 30% which contributed to 
decrease in choline phosphorylation in all hypoxic cells. The high Km of choline 
kinase for ATP and significant decrease in ATP levels in cancer cells could in 
part contribute to inhibition of phosphorylation in addition to reductions of choline 
kinase activity. Inhibition of choline phosphorylation due to ATP depletion was 
also reported in hypoxic HL-1 cardiomyocytes (Sarri et al., 2006) and AICAr 
treated hepatocytes (Jacobs et al., 2007). Pronounced decrease in choline 
phosphorylation in PC-3 and ovarian cancer cells as compared to other cells 
suggests that factors other than choline kinase and ATP may have a role in 
determining choline uptake and trapping. More work is needed to understand the 
mechanism of inhibition of choline phosphorylation in hypoxia in cancers.  
To further confirm the results from tracer study for PC-3 cells, steady state 
concentrations of choline metabolites were measured. It was observed that PC-3 
cells maintained a high ratio of steady-state concentrations of phosphocholine to 
choline irrespective of oxygenation status but hypoxia increased the steady-state 
choline concentration 10-fold while decreasing phosphocholine concentration by 
15%. Increased steady-state choline/phosphocholine concentration ratio and 
decreased uptake and phosphorylation of exogenous radiolabeled choline in 
hypoxic PC-3 cells strongly suggest that hypoxia mediated inhibition of choline 
phosphorylation. This strongly supported the radiotracer studies. 
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It is well known that metabolites participating in rate-limiting metabolic reactions 
are regulated by modulation of associated catalyzing enzymes (Newsholme and 
Crabtree, 1973). A disequilibrium ratio (MAR/Keq) that is << 1 implies that the 
reaction be considered far from equilibrium or rate limiting. From this principle, 
Infante et al. showed that the reaction catalyzed by choline kinase is rate limiting 
in rat liver (Infante, 1977; Infante and Kinsella, 1978). Present study corroborates 
previous work showing that modulation of choline kinase can change 
concentration of choline metabolites in cancer cells.  
Uptake of tracers in subcutaneous 9L tumor at 5 min and 20 min was 
dominated by choline radiotracers in their nonmetabolized form. This was in 
accordance with the inhibition of choline phosphorylation that was seen in 
hypoxic 9L glioma cultured cells. These results suggest that hypoxia can explain 
the low levels of choline phosphorylation in the 9L glioma tumor model. This 
notion is further supported by earlier reports demonstrating extreme levels of 
hypoxia (median pO2 value 5.5-7 mm Hg (~ 1% O2)) resulting from low perfusion 
in the same subcutaneous 9L tumor (Jenkins et al., 2000). Low perfusion rate 
and low choline retention rate was also confirmed by perfusion and choline 
retention quantitative maps generated from tumor sections. The results of choline 
tracer studies with cultured cancer cells and 9L glioma subcutaneous tumor may 
best interpolate to human tumors that are characteristically hypoxic. It follows 
that the utility of choline tracers in the clinical setting may be impacted by tumor 
hypoxia. Tumors that are hypoxic may exhibit low uptake of choline based 
tracers as governed by increased efflux of nonmetabolized tracer and decreased 
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metabolic trapping (phosphorylation). Thus, interpretations of clinical PET images 
with choline radiotracers should bear in mind that choline tracer uptake may 
underestimate tumor proliferation (or viability) in hypoxic tumor regions. 
Tumor hypoxia may profoundly lower choline metabolic trapping in cancer 
cells. Thus, choline tracer retention may be related to tumor oxygenation status 
through effects on choline kinase activity. This effect has clear implications for 
interpretation of clinical PET images with choline radiotracers; tumor proliferation 
(or viability) may be underestimated in hypoxic tumor regions. 
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CHAPTER II 
 
Hypoxia downregulates expression of choline kinase α (ChKα) mediated by 
hypoxia inducible factor 1α (HIF1α) 
1. Abstract 
In this study, the effects of chronic hypoxia on ChKα expression were 
examined in PC-3 and LNCaP prostate cancer cells. RT-PCR analysis showed 
decreased transcription of ChKα gene in hypoxic PC-3 correlating with 
decreased enzymatic activity of choline kinase in hypoxic cell extracts. Over-
expression of HIF1α in normoxic PC-3 cells decreased choline kinase mediated 
choline retention. Alignment of nucleotide sequence of the putative promoter 
region of ChKα from rat, mouse, chimpanzee and human revealed a highly 
conserved hypoxia responsive element, HRE7. Electrophoretic mobility shift 
competition/supershift assay and chromatin immunoprecipitation (ChIP) assay 
confirmed binding of HIF1 to HRE7. To understand the transcription control 
of ChKα under hypoxia, a putative promoter of ChKα was isolated from PC-3 
genomic DNA and cloned into a luciferase (Luc) based reporter vector system. In 
PC-3, hypoxia decreased the expression of Luc under the control of the ChKα 
promoter. Mutation of HRE7 and subsequent Luc reporter assays demonstrated 
that this HRE is involved in hypoxia/HIF1-mediated regulation of ChKα. The 
results suggest that the decreased choline phosphorylation in PC-3 cells in 
response to hypoxia is mediated in part by transcriptional control of ChKα 
expression via HIF1 binding to HRE7. 
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2. Introduction 
Tumors in general are heterogeneous in nature with regions of hypoxia 
and normoxia that are expected to have different metabolic profile. My work with 
different cancer cell lines discussed in the previous chapter, showed significant 
inhibition of choline phosphorylation in hypoxic condition (1% O2) as compared to 
normoxic (21% O2) cells. Inhibition of choline phosphorylation by hypoxia has not 
been reported as a universal response in cancer cell line and my previous 
observation provides a unique opportunity to understand the mechanism behind 
decreased choline metabolism in hypoxic cancer cells. Recently, increased 
choline kinase expression was reported by western blot in PC-3 cells exposed to 
24 h hypoxia (1% O2) (Glunde et al., 2008). CoCl2 is known to stabilize HIF-1 
protein (Groenman et al., 2007) as seen in hypoxia and is used to induce 
chemical hypoxia. HIF-1 activation of HREs within the putative ChKα promoter 
region was suggested to increase choline kinase expression under hypoxia or 
exposure to CoCl2. The above mentioned report of increased expression of 
choline kinase in hypoxia contradicts my results on uptake of choline in hypoxia 
and recent microarray studies with PC-3 cells and MCF-7 breast cancer cells that 
showed ChKα to be significantly down-regulated by chronic hypoxia (Ackerstaff 
et al., 2007; Elvidge et al., 2006). 
Although ChKα was shown to be up-regulated in hypoxia using promoter 
analysis, non-overlapping regions were identified in the ChKα promoter that can 
potentially up-regulate (HRE 3-6) or down-regulate ChKα (in red box) under 
chronic hypoxia, suggesting complex regulation of ChKα (Figure 17).  
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Figure 17. Schematic diagram of upstream promoter of human ChKα: 
Promoter region (in red box) is responsible for negative regulation of ChKα in 
hypoxia. Modified from Glunde et al., 2008. 
 
The goals of the present study were to 1) evaluate the equilibrium status 
of the choline phosphorylation reaction in PC-3 cells to theoretically predict the 
effect of choline kinase inhibition on choline phosphorylation in these cells, 2) 
quantify ChKα mRNA expression and choline kinase activity in hypoxic PC-3 
cells, 3) determine whether modulation of choline uptake and choline kinase 
activity is a HIF1α dependent response in PC-3 cells and 4) characterize the 
ChKα promoter associated with HIF1α mediated regulation of ChKα expression.  
This study clarified that expression of ChKα is reduced in hypoxic PC-3 
cells and identified a novel HIF1 binding HRE site that mediates down-regulation 
of ChKα in hypoxic PC-3 cells. 
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3. Materials and Methods  
3.1. Material chart 
Dr. Bunn HF, (Hematology 
Divison, Brigham & Women’s 
Hospital, Boston, MA). 
HIF1α/ pcDNA3 plasmid 
HIF1α(∆ODD)/ pcDNA3 plasmid 
ATCC, Manassas, VA 
PC-3 and LNCaP prostate cancer 
cells 
RPMI-1640 medium  
Fetal bovine serum  
0.25% Trypsin-EDTA 
Bio-rad, Hercules, CA 
Bio-Rad protein assay reagent 
SDS 
Mini-Trans Blot system 
Mini-Protean electrophoresis 
system 
TBE polyacrylamide gel 
Eppendorf, Westbury, NY Centrifuge 5415R 
Roche, Indianapolis, IN 
Complete Protease Inhibitor 
Cocktail Tablets 
Integrated DNA technology Inc., 
Coralville, IA 
Oligonucleotide primers 
Invitrogen, Carlsbad, CA 
Oligofectamine LTX 
Quant-IT Picogreen quantification 
kit 
Promega, Madison, WI 
pGL4.74[hRluc/TK]  
pGL4.10 [luc2] 
Dual-Glo® Luciferase Assay 
System 
New England BioLabs, Ipswich, 
MA 
Phusion High-Fidelity PCR Master Mix 
with GC Buffer  
T4 DNA ligase 
Restriction enzymes 
Stratagene, La Jolla, CA 
QuikChange Site-Directed 
Mutagenesis Kit 
QIAGEN, Valencia, CA 
RNeasy Plus mini Kit  
DNeasy Blood & Tissue Kit 
QIAquick PCR purification Kit  
minElute PCR purification Kit 
QuantiTect SYBR Green PCR Kit 
Q-solution 
gDNA Eliminator column 
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Perkin Elmer, Waltham, MA Victor 3 Multiplate reader 
GE Healthcare, Piscataway, NJ Amersham Hyperfilm ECL 
Santa Cruz Biotechnology, 
Santa Cruz, CA 
anti-β-actin  
Anti-goat IgG HRP conjugate 
Sigma, St. Louis, MO 
Neomycin 
RIPA lysis buffer  
protease inhibitor cocktail 
Novus Biologicals, Littleton, CO polyclonal anti-HIF1  
Piercenet, Rockford, IL 
LightShift Chemiluminescent EMSA Kit  
Chemiluminescent Nucleic acid 
Detection Module 
Biodyne B Nylon membrane 
Eurofins MWG Operon, 
Huntsville, AL 
PAGE purified biotinylated or 
unbiotinylated oligonucleotides 
BD Biosciences, San Jose, CA monoclonal anti-HIF1α 
Applied Biosystems, Foster City, 
CA 
 
TaqMan gene expression assays 
 
3.2. Isolation of total RNA from cancer cells 
 RNA was isolated from 3 X 106 cancer cells using RNAeasy Mini Kit 
(QIAGEN Inc., Valencia, CA). The lysate was homogenized using QIAshredder 
spin column (QIAGEN Inc., Valencia, CA) according to manufacturer’s instruction. 
Total DNA was separated from RNA using gDNA Eliminator column. The 
concentrations of total RNA were determined by absorbance at 260 nm with a 
Nanodrop spectrophotometer (Thermo Scientific, Wilmington, DE). 
3.3. Quantification of mRNA signal 
Expression of mRNA for ChKα was measured in the two cancer cell lines 
in normoxic and hypoxic conditions by real-time PCR using TaqMan® Gene 
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Expression Assays on ABI PRISM 7700 Sequence Detection System (Applied 
Biosystems, Foster City, CA). ~ 5 µg of total RNA of each sample was used to 
generate cDNA and the real-time PCR reactions were carried out following the 
manufacturer's protocol. 18S rRNA was used as an endogenous control. 
3.4. Western blot analysis 
Cells were homogenized with radioimmunoprecipitation assay (RIPA) lysis 
buffer (SIGMA) containing protease inhibitor cocktail. Cell extracts were obtained 
by centrifugation for 10 min at 4°C and 8000 x g. Protein concentrations were 
determined by the Bio-Rad assay. Equal amounts of protein were separated on 
SDS-polyacrylamide gels; fifty µg of protein was separated for HIF1α and β-actin. 
At the end of separation, the proteins were transferred to a PVDF (polyvinylidene 
difluoride) membrane by the wet blotting method, and probed with antibodies 
directed against hypoxia inducible factor 1α (HIF1α) and β-actin. The amounts of 
bound antibodies were accessed by the peroxidase activity of horseradish 
peroxidase-conjugated secondary antibody as detected by Amersham ECL Plus 
Western Blotting Detection Reagents.  
3.5. Over-expression of hypoxia inducible factor 1α (HIF1α) 
Full length HIF1α and HIF1α (∆ODD) expression constructs expressing 
respective proteins (Figure 18) were kindly provided by Dr. H Franklin Bunn 
(Hematology Divison, Brigham & Women’s Hospital). Stable PC-3 cell lines 
expressing HIF1α were generated following transfection with Lipofectamine LTX 
reagent (Invitrogen, Carlsbad, CA, USA) and neomycin selection (200 µg/ml). 
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Figure 18. Schematic diagram of HIF1α inserts in the expression vector. 
These inserts were used in the expression vector for expressing HIF1α protein 
and oxygen stable HIF1α (∆ODD) protein without oxygen dependent degradation 
domain. 
 
3.6. Isolation of promoter region upstream of choline kinase α (ChKα)  
The genomic DNA was extracted from PC-3 using DNeasy Blood & Tissue 
Kit (Qiagen) and quantified. Putative promoter region upstream of ChKα was 
amplified from genomic DNA using Phusion High-Fidelity PCR Master Mix with 
GC Buffer (NEB, Ipswich, MA, USA). The identity of the promoter was confirmed 
using nested PCR amplifications and sequencing. Details of primers used are 
described in Table 6. Amplified full length promoter had restriction sites, Acc651 
and HindIII at the 5’ and 3’ end, respectively, for directed cloning into the 
pGL4.10 [luc2] vector (Promega, Madison, WI, USA). 
3.7. Promoter alignment 
To identify conserved putative HIF1α binding site alignment of promoter 
region upstream of rat, mouse, chimp and human choline kinase α was done 
using online Clustal W program, http://www.ebi.ac.uk/Tools/clustalw2/index.html. 
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Table 6. Sequences of primers used for ChKα promoter isolation and 
nested PCRs. 
 
 
3.8. Site-directed mutagenesis 
Mutation at the conserved putative HIF1α binding site (5’-TCGTGC-3’) to 
(5’-AGCATT-3’) was performed using QuikChange Site-Directed Mutagenesis Kit 
(Stratagene, La Jolla, CA, USA).  
 
Region 
 
Primer 
 
Amplicon 
size (bp) 
 
Full length 
promoter 
 
Forward primer 
5’-GCGGGTACCTGAGGCAACCTCTTCCTCC-3’ 
Reverse primer 
5’-GCGAAGCTTTGCCCGACAGGCGGCCGA-3’ 
 
 
2190 
Nested PCR 1 
 
Forward primer 
5’-GCGGGTACCTGAGGCAACCTCTTCCTCC-3’ 
Reverse primer 
5’-GACCGTGACTAACGCACCTT-3’ 
 
1091 
Nested PCR 2 
 
Forward primer 
5’-TGGAAGACTGTGAACTCCCC-3’ 
Reverse primer 
5’-GCTCAGTGGGTGTGATTTT-3’ 
 
658 
Nested PCR 3 
 
Forward primer 
5’-AAGGTGCGTTAGTCACGGTC-3’ 
Reverse primer 
5’-GCGAGAGGACTAGGCTCAGA-3’ 
 
1081 
Nested PCR 4 
 
Forward primer 
5’-GAGGGGTCCAAGGAAACTTT-3’ 
Reverse primer 
5’-GCGAAGCTTTGCCCGACAGGCGGCCGA-3’ 
 
584 
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3.9. DNA sequencing 
DNA sequences of all plasmids were confirmed by sequencing by DNA 
Core Sequencing Facility at Brigham and Women’s Hospital, Boston, MA. 
3.10. Transient expression assays  
PC-3 cells were cultured in RPMI-1640 medium containing 10% fetal 
bovine serum (FBS) on 100 mm dishes at 37°C with 5% CO2 in air. When cell 
confluence reached about 80%, the media were removed and the cells were 
washed with 1X phosphate buffered saline (PBS). The cells were detached with 
1X Trypsin-EDTA (0.25% Trypsin, 1 mM EDTA). After detaching, one third of the 
cells were transferred to fresh RPMI-1640 medium containing 10% FBS on 100 
mm dishes and incubated at 37°C with 5% CO2. For transient expression, PC-3 
cells were inoculated into 6 well plates and incubated overnight in RPMI-1640 
medium containing 10% FBS at 37°C with 5% CO2. Following overnight 
incubation, the media were changed to OPTI-MEM reduced serum medium. The 
firefly luciferase reporter plasmid, pGL4.10 [luc2] containing the human ChKα 
promoter region and pGL4.74[hRluc/TK], the internal control plasmid expressing 
renilla luciferase, were cotransfected using Lipofectamine LTX following the 
instructions of the manufacturer. Following 24h of normoxia (21% O2) or hypoxia 
(1% O2), transfected cells were lysed and expression assays were performed 
using Dual-Glo® Luciferase Assay System (Promega). 
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3.11. Electrophoretic Mobility Shift Assay (EMSA)  
Nuclear proteins were prepared using the NE-PER nuclear and 
cytoplasmic extraction kit (Piercenet, Rockford, IL, USA). Complementary PAGE 
purified biotinylated or unbiotinylated oligonucleotides (Eurofins MWG Operon, 
Huntsville, AL, USA) were annealed to make double-stranded probes. Details of 
the probes are described below (Table 7). The labeled probes were incubated 
with hypoxic PC-3 cell nuclear extracts according to manufacturer’s protocol in 
LightShift Chemiluminescent EMSA Kit (Piercenet). The DNA-protein complexes 
was resolved in 5% nondenaturing TBE polyacrylamide gel (Biorad, Hercules, 
CA), followed by wet transfer to Biodyne B Nylon membrane (Piercenet). 
Complex was detected using Chemiluminescent Nucleic acid Detection Module 
(Piercenet). For competition assays, 4 pmol (200 times excess) unlabeled probes 
and 0.5 µg monoclonal anti-HIF1α (BD Biosciences) was used. For supershift 
assay, 0.5 µg polyclonal anti-HIF1α (Novus Biologicals, Littleton, CO) was used. 
Incubation without nuclear extract was used as a negative control.  
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Table 7. Sequence of double stranded (ds) probe used for electrophoretic 
mobility shift assays.  
 
 
Probe 
 
Sequence of first strand of the ds probe 
 
Reference 
 
Labeled 
HRE7 
 
Biotin-5’-
GCGGCCGGCGCTCCTCGTGCGGCGGCGGCA
GAGG-3’ 
 
 
Present work 
Unlabeled 
HRE7 
5’-
GCGGCCGGCGCTCCTCGTGCGGCGGCGGCA
GAGG-3’ 
Present work 
Unlabeled 
HRE 
upstream 
VEGF 
5'-TGCATACGTGGGCTCCAACAG-3’ 
(Nguyen and 
Claycomb, 
1999) 
 
3.12. Chromatin immunoprecipitation (ChIP) assay 
The assay was performed based on standard ChIP assay protocol (Xia 
and Kung, 2009; Xia et al., 2009). Chromatin was sonicated to 500- to 1,000-bp 
fragments and immunoprecipitation was carried out with polyclonal anti-HIF1  
(Novus Biologicals). Chromatin (sonicated or immunoprecipitated) were purified 
by standard phenol-chloroform procedure followed by column purification using 
minElute PCR purification kit (Qiagen). DNA was quantified by Quant-IT 
Picogreen quantification kit (Invitrogen, USA). Equal amount of unprocessed 
(Input) and immunoprecipitated (ChIP) chromatin was used for PCR. Traditional 
PCR was performed to standardize conditions for quantitative PCR. Q-solution 
(Qiagen) additive was included in amplification of promoter region spanning the 
HRE7 site due to high GC content of the amplicon. Fold enrichment of a 
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promoter region was assessed by performing quantitative PCR using QuantiTect 
SYBR Green PCR Kit (Qiagen) with chromatin samples taken before (input) and 
after immunoprecipitation (ChIP). Details of the primers and calculations for fold 
enrichment are described below (Table 8). 
 
Table 8. Sequences of primers used for PCR for amplification of promoter 
regions in ChIP assay.  
 
 
Promoter 
region 
 
Forward primer 
 
Amplicon 
size (bp) 
 
Reference 
 
Negative 
control 
region 
(10kb 
upstream 
of VEGF) 
 
Forward primer 
5’-
TTGATGTAGGCAGAACCTGGGAGA-
3’ 
Reverse primer 
5’-
CCCGCCCAGAAAGGTTTGTTAAGT-
3’ 
 
 
159 
 
(Xia and 
Kung, 
2009; Xia 
et al., 
2009) 
Positive 
control 
region 
(HRE 
upstream 
ENO1) 
 
Forward primer 
5’-
AGATAGGACCGGTGAGCCGAACT-
3’ 
Reverse primer 
5’-
AAAGTTGTCAGCAAGGTCGAGGG-
3’ 
 
171 (Xia and 
Kung, 
2009; Xia 
et al., 
2009) 
HRE7  
Forward primer 
5’-AATCAGTGGCGAGCGCGAGG-3’ 
Reverse primer 
5’-TGGAGCGGGGATGTGCTGCT-3’ 
 
102 Present 
work 
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3.13. Statistical analysis  
Results are presented as means ± standard deviation. Student’s t-test was 
applied for statistical evaluation and a p-value <0.05 was considered significant. 
4. Results  
4.1. Hypoxia decreases the expression of choline kinase α (ChKα) in 
prostate cancer cells 
Hypoxic exposure to PC-3 cells was able to significantly elevate the 
expression of HIF1α protein as shown by western blot analysis (Figure 19). 
Existence of a HIF1α dependent response in hypoxic PC-3 was confirmed with 
RT-PCR, showing significantly increased mRNA levels of VEGF gene (2.5 fold) 
under chronic hypoxia (Table 9). Supporting the decreased choline kinase 
activity, RT-PCR analysis showed significant decrease in mRNA levels of ChKα 
gene in PC-3 cells. Similar effect of hypoxia on HIF1α, VEGF and ChKα 
expression was seen in another prostate cancer cell line, LNCaP (Table 9). 
 
Figure 19. Effect of hypoxia on expression of HIF1α HIF1α protein levels 
shown by western blot  
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Table 9 Effect of 24h of hypoxic (1% O2) exposure on expression of ChKα 
and VEGF mRNA 
Values less than 1 means down-regulation and values more than 1 means up-
regulation of mRNA expression in hypoxia 
  
4.2. Over-expression of HIF1α decreases uptake and phosphorylation of 
choline in prostate cancer cells  
Hypoxia decreased choline kinase activity and choline uptake in PC-3 
cells but it was not clear that this reduction was mediated by HIF1α. Stable cell 
lines over-expressing full length HIF1α (negative control) and HIF1α lacking 
oxygen dependent degradation domain (ODD) were successfully generated. The 
expression status of these cell lines were confirmed by western blot with 
monoclonal antibody against HIF1α (Figure 20a). Deletion of ODD in HIF1α 
protein was able to prevent degradation of this protein in normoxic condition. 
Choline uptake (Figure 20b) and choline activity (Figure 20c) were both 
decreased in normoxic PC-3 cells that were over-expressing stabilized HIF1α, 
thus mimicking the effects of hypoxia. 
4.3. HIF1 binding sites and promoter alignment 
HIF1 regulates gene expression by binding to hypoxia response core 
element(s) (HRE, 5’- CGTG - 3’) in the proximal promoter region of the hypoxia 
responsive genes (Semenza et al., 1998). In the promoter region upstream of 
 mRNA level ratio (Hypoxia/Normoxia) 
                ChKα                          VEGF (+ control)  
PC-3 0.74 ± 0.12 2.44 ± 0.4 
LNCaP 0.71 ± 0.13 5.05 ± 0.81 
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human choline kinase α (hChKα), 6 previously identified HRE sites relative to +1 
translation start site (Glunde et al., 2008) were confirmed as HRE1 (-1723); 
HRE2 (-1460); HRE3 (-1027); HRE4 (-880); HRE5 (-851); and HRE6 (-825) 
(Figure 21). In addition to these, two putative HRE sites were newly identified as 
HRE2B (-1422) and HRE7 (-222). DNA sequence alignment of promoter region 
upstream of the hChKα (Glunde et al., 2008), chimp (from NCBI), rat (Uchida et 
al., 1994) and mouse (from NCBI) showed that out of these 8 putative HRE sites 
in the proximal promoter region only HRE7 positioned at -222 nucleotide was 
conserved across all species (Figure 21). 
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Figure 20. Effect of HIF1α on choline metabolism. (a) Over-expression of full 
length HIF1α and HIF1α∆ODD+ in PC-3 cells as shown by western blot on (b) 
choline tracer uptake (n = 3, each condition) and (c) choline kinase activity (n = 3, 
each condition). The cells expressing variant of HIF1α lacking the oxygen 
dependent degradation domain (ODD) showed significantly (p< 0.05) reduced 
[3H]choline uptake and choline kinase activity. * p < 0.05 Vs values in PC-3 
HIF1α+ control using unpaired t-test. 
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Figure 21. Nucleotide alignments of segments of promoter region upstream 
of ChKα gene: Alignment of human, chimp, rat and mouse showing 8 putative 
HRE sites in the promoter region of ChKα promoter. The schematic diagram and 
HRE nomenclature was adapted from Glunde et al., (2008). 
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4.4. Mutation of a putative HRE site reduced the inhibitory effect of HIF1α 
on ChKα promoter activity in PC-3 prostate cancer cells  
The proximal promoter (~ 2.2 Kb) upstream of hChKα was successfully 
isolated from PC-3 genomic DNA and cloned into luciferase vector construct. 
This was confirmed with nucleotide sequencing and amplification with nested 
primers. Mutation at the conserved HRE7 site (5’-TCGTGC-3’) to (5’-AGCATT-3’) 
in the promoter of the construct was successful and confirmed by nucleotide 
sequencing. In normoxic conditions, there was no difference in promoter 
mediated luciferase signal from PC-3 cell lines expressing wild type HRE7 and 
mutated HRE7 (Figure 22). In contrast, in hypoxic and DMOG treated PC-3 cells, 
there was a significant decrease in luciferase signal from PC-3 cells expressing 
wild type HRE7 as compared to normoxic cells and cells with no DMOG 
exposure. However, in hypoxic or DMOG treated cells expressing mutated HRE7, 
there was a slight increase in luciferase signal when compared to normoxic 
levels or cells expressing wild type HRE7 (Figure 23).  
 
 
 
Figure 22. Schematic diagram of human ChKα promoter showing the site 
and description of mutation. HRE nomenclature was adapted from Glunde et 
al., 2008. 
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Figure 23. Promoter - reporter construct assay: Wild type and mutated ChKα 
gene promoter dependent luciferase signal from PC-3 cells expressing wild type 
promoter and mutated promoter in (a) normoxia (21% O2) and hypoxia (0% O2), 
and in (b) presence of 0 mM DMOG and 2 mM DMOG. Hypoxia (*p < 0.05 Vs 
normoxia) and DMOG (#p< 0.1 Vs 0mM DMOG) reduced luciferase signal with 
wild type ChKα promoter but had no significant effect with the mutated HRE7. 
 
4.5. HIF1α is able to bind to the putative HRE site in ChKα promoter 
An electrophoretic mobility shift assay (EMSA) was performed to assess 
the binding ability of HIF1 to HRE7 in in vitro conditions (Figure 24). Lane 1 and 5 
showed only a single band of unbound or free biotinylated probe (containing 
HRE7 site). With the addition of the nuclear protein extract of hypoxic PC-3 cells 
in the binding reaction, an extra band of decreased mobility was observed 
(Figure 24; Lane 2 and 6). This extra band represented binary complex HIF1-
biotinylated probe complex. The binary complex was not visible when the binding 
assay was performed with unlabeled probe (with HRE7 site) added 200 times in 
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excess of the biotinylated probe (Figure 24; Lane 3), demonstrating saturability of 
binding. A significant decrease in intensity of the extra band was also seen when 
unlabeled probe with known functional HRE site upstream of HIF1 regulated 
VEGF gene was added in 200 times in excess of the biotinylated probe (Figure 
24; Lane 4). Incubation with specific monoclonal antibody against HIF1  
prevented binding of HIF1 to biotinylated probe (Figure 24; Lane 7). Specific 
polyclonal antibody against HIF1α did not disrupt the HIF1-biotinylated probe 
complex but formed a tertiary complex of anti-HIF1α, HIF1, and biotinylated 
probe. This tertiary complex was seen as an extra band on acrylamide gel that 
was above the band represented by the HIF1α-biotinylated oligo binary complex 
(Figure 24; Lane 8). This supershift of biotinylated probe was caused due to 
significant decrease in mobility of the tertiary complex. 
A ChIP assay was performed to determine whether HIF1 binds to the 
putative HRE 7 site in vivo in normoxic and hypoxic PC-3 cells. Hypoxia was 
mimicked by incubation with 2 mM DMOG. Using traditional PCR, we could 
observe significant enrichment of promoter regions with HRE7 (Figure 25a) after 
immunoprecipitation as compared to input samples in hypoxia. The enrichment in 
hypoxia and normoxia was quantified from threshold Ct values obtained by 
quantitative PCR (Figure 25b). Based on quantitative PCR results, following ChIP, 
HRE7 showed 7.7-fold enrichment in hypoxia as compared to 2.3- fold 
enrichment in normoxia, suggesting increased binding of HIF1 to HRE7 in 
hypoxic conditions.  
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Figure 24. In vitro binding of HIF1 to HRE 7 site of human ChKα promoter. 
Electrophoretic mobility shift competition and supershift assay using nuclear 
extract from hypoxic PC-3 cells. HRE7CHK - 200 fold excess of unlabeled probe 
with HRE7 site; HREVEGF - 200 fold excess of unlabeled probe with functional 
HRE upstream of VEGF; mHIF1Ab - monoclonal anti - HIF1α and pHIF1Ab- 
polyclonal anti-HIF1α. 
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Figure 25. In vivo binding of HIF1 to HRE 7 of hChKα promoter region in 
PC-3 cells by ChIP assay. Following 24h exposure to normoxia (0 mM DMOG) 
or hypoxia (2 mM DMOG), chromatin was cross-linked, sonicated and 
immunoprecipitated with polyclonal anti-HIF1α. PCR was performed with 
reverse-crosslinked chromatin samples taken before (input) and after 
immunoprecipitation (ChIP). Enrichment of chromatin fragment including the 
specific HRE in immunoprecipitated chromatin was compared to unprocessed 
chromatin (input) by (a) representative gel of semi-quantitative PCR and gel 
electrophoresis and (b) quantitative PCR (n = 5, each condition). Fold enrichment 
calculated by quantitative PCR was normalized with negative control. Negative 
control used was a region upstream of VEGF gene that contained no HRE site. 
DMOG caused a significant fold increase in enrichment of HRE7. * p < 0.05 Vs 
values in 0mM DMOG (control) using unpaired t-test. 
 
5. Discussion 
We are the first to report a decreased expression of ChKα in hypoxic PC-3 
and LNCaP prostate cancer cells using RT-PCR. Similar findings with microarray 
analysis were reported in hypoxic PC-3 and MCF-7cells (Elvidge et al., 2006; 
Ackerstaff et al., 2007). The decreased mRNA levels correlated with decreases 
in choline kinase activity in protein extracts of hypoxic PC-3 cells. These results 
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suggest hypoxia-induced transcriptional control of the ChKα gene. In MCF-7, 
siRNA HIF1α silencing has been previously reported to abolish the negative 
effect of hypoxia on ChKα expression (Elvidge et al., 2006; Ackerstaff et al., 
2007). In the present study, we have shown that over-expression of HIF1α in 
normoxic PC-3 cells is sufficient to decrease choline uptake and choline kinase 
activity independent of hypoxia. Thus, there is strong evidence of HIF1α 
mediated negative control of choline phosphorylation in cancer cells. 
Transcriptional control of hypoxia responsive genes by HIF1α is mediated 
by binding of HIF1α to HRE sites in the regulatory promoter region of a target 
gene (Caro, 2001). In our analysis of the promoter region of the hChKα we 
confirmed the 6 HRE sites previously reported with the sequence 5'-G/CCGTG-3' 
(Glunde et al., 2008). In our study we included two additional potential HIF1α 
binding sites with sequence 5'-TCGTG-3' (HRE2B and HRE7) following a 
previous report on the ability of 5'-TCGTG-3' to bind to HIF1α in promoter region 
of hypoxia responsive phosphoglycerate kinase -1 (PGK-1) (Okino et al., 1998). 
Hypoxia-induced inhibition of choline phosphorylation and choline kinase activity 
has been reported in cancer cell lines derived from mouse (Sarri et al., 2006) and 
humans (Hara et al., 2006). Alignment of nucleotide sequence of promoter of 
ChKα gene from rat, mouse, chimp and human was performed in order to find 
conserved putative HRE sites that could potentially be mediating a universal 
hypoxic response. Alignment of promoters revealed that not all putative HRE 
core sites are conserved across species. We found only one well conserved HRE 
site, HRE7 at the -222 nucleotide position. 
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Binding of HIF1 to HRE7 was confirmed by electrophoretic mobility shift 
assay (EMSA). Furthermore, the HRE from the promoter region of VEGF 
(Nguyen and Claycomb, 1999) gene was able to compete with the HRE7 of 
ChKα for HIF1 binding in nuclear extracts derived from hypoxic PC-3 cells. It was 
interesting to note that HIF1 showed a higher binding affinity for HRE7 than for 
the HRE upstream of VEGF gene. Specific monoclonal antibody against HIF1α 
inhibited binding of HIF1 to HRE7. In addition, a polyclonal antibody against 
HIF1α was able to form a tertiary complex with HRE7-HIF1 causing supershift on 
the acrylamide gel. These results strongly support in vitro binding of HIF1 to 
HRE7. The in vivo binding of HIF1 to the conserved HRE7 was confirmed by 
ChIP assay. Following DMOG exposure, significant enrichment of chromatin 
fragments with HRE7 was found, indicating HRE7 is sensitive to changes in HIF1 
levels.  
Observations in the present study are in well accordance with previously 
reported microarray and choline tracer studies with hypoxic PC-3 cells and MCF-
7 cells (Ackerstaff et al., 2007; Elvidge et al., 2006; Hara et al., 2006). In addition, 
the present study also corroborate the work of Glunde et al.,2008 that suggested 
involvement of HRE 3-6 in hypoxia mediated potential up-regulation of ChKα 
expression. It should be noted that in their study, HRE 3-6 exerted a positive 
effect on expression of the reporter in hypoxia only when the highly repressive 
downstream +1 to -338 nucleotides was deleted from the promoter constructs. 
Based on the present work we have shown that this highly repressive 
downstream ~ 338bp ChKα promoter region contains the conserved HIF1 
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binding HRE7 site. The role of HRE7 in transcriptional down-regulation of ChKα 
was confirmed when the mutation of HRE7 abrogated the transcriptional 
repressive control of full length ChKα promoter under hypoxia or DMOG 
exposure in the promoter-luciferase construct assays.  
From a survey of the literature on various genes, HIF1α is reported to 
exclusively up-regulate (Semenza et al., 1994; Firth et al., 1995; Semenza et al., 
1996; Riddle et al., 2000; Chen et al., 2001) or down-regulate (Eltzschig et al., 
2005; Rosenberger et al., 2007; Zheng et al., 2009) its target gene. The 
presence of multiple HIF1 binding HRE sites (HRE 3-6 and HRE7) in the ChKα 
promoter region with opposing effects on expression of ChKα in hypoxia appears 
to be unique. Thus the regulatory mechanisms whereby HIF1 influences ChKα 
expression are complex and deserve further study.  
It is tempting to speculate that HIF1 mediated transcriptional down-
regulation of ChKα gene could represent a survival strategy for hypoxic cancer 
cells. Choline phosphorylation is ATP consuming. Thus, a reduction in choline 
kinase activity may have an ATP sparing effect in energy starved hypoxic 
conditions. Cancer cells must survive hypoxic stress by prioritizing use of ATP in 
various ATP requiring processes in the cell. Additional work is needed to further 
understand the role and importance of HIF1 mediated inhibition of choline kinase 
expression/choline phosphorylation in hypoxic conditions. High Km for ATP for 
choline kinase makes it possible for choline kinase to be modulated by changes 
in ATP levels. Increased choline phosphorylation in cancer cells is the basis for 
choline-based imaging modalities for cancer diagnosis and therapy monitoring. 
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Tumors that are hypoxic may exhibit low accumulation of choline as governed by 
increased efflux of non-metabolized choline and decreased metabolic trapping 
(phosphorylation). Thus, interpretations of total choline signal from MRSI and 
clinical PET images with choline radiotracers should bear in mind that the 
hallmark up-regulations of choline-containing metabolites, choline uptake and 
choline phosphorylation may be significantly blunted in hypoxic tumor regions. 
Anticancer therapies that modulate tumor hypoxia (Yeo et al., 2004) may have 
secondary effects on choline kinase expression and activity. Therefore, the 
potential impact of changes in tumor oxygenation on the signals of choline-based 
imaging methods should be considered when imaging studies are used to 
noninvasively monitor treatment response in hypoxic tumors. 
My present work provides strong evidence that choline phosphorylation 
step is far from equilibrium in human prostate cancer cell line, PC-3 and that 
hypoxia down-regulates ChKα expression. This regulation involves transcriptional 
level mediation by HIF1 at the conserved HRE7 site in ChKα promoter.  
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CHAPTER III 
 
Choline kinase expression and hypoxia confers a survival advantage to 
early stage prostate cancer cells 
1. Abstract 
ChKα and hypoxia are associated with aggressive tumor phenotype. This 
study shows how prostate cancer cells, PC-3 (late stage and androgen-
independent cell lines) and LNCaP (early stage and androgen-dependent cell 
lines), respond to over-expression of ChKα and chronic hypoxia (1% O2) 
(independently and in combination). Over-expression of ChKα decreased cell 
proliferation rate and cell invasion potential of PC-3 cells irrespective of exposure 
to normoxia or hypoxia. On the other hand, in LNCaP cells, over-expression of 
ChKα and hypoxia independently increased proliferation rate and markedly 
increased cell invasiveness correlating with increased expression of pro-
migratory factor, uPa. In both cell lines, over-expression of ChKα had a positive 
effect on anchorage independent growth which was more pronounced in LNCaP 
than in PC-3 but hypoxia inhibited the anchorage independent growth in both cell 
lines. In conclusion, differential effects were observed in PC-3 and LNCaP cells 
lines in response to ChKα over-expression and hypoxia. Greater enhancements 
of malignant phenotypes were observed in the more differentiated LNCaP cell 
line. The results suggests that increased ChKα activity and hypoxic tumor 
microenvironment are important for progression of early-stage, androgen-
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dependent prostate cancer but confer little survival advantage in undifferentiated, 
androgen-independent prostate cancers. 
Introduction  
All human tumors encounter hypoxia during their development 
(Anastasiadis et al., 2002). It has been demonstrated that tumor hypoxia can be 
an independent prognostic indicator of poor clinical outcome in patients with 
head and neck cancers, cervical cancers, and soft tissue sarcomas (Anastasiadis 
et al., 2002). Hypoxia is common in primary prostate tumors too and is usually 
associated with poor prognosis (Movsas et al., 1999). Recent studies show that 
prostate cancer cells are able to survive tumor hypoxia (≤ 1% O2). These 
surviving cancer cells develop aggressive malignant phenotypes and become 
resistant to androgen ablation, radio- and chemotherapy (Movsas et al., 2000).  
To understand the survival adaptations in hypoxic prostate tumors, 
experimental model systems of prostate cancer, LNCaP and PC-3 can be useful. 
These two cell lines represent different stages of prostate cancer disease 
progression. LNCaP represents androgen-dependent, early stage cancer with a 
low invasion potential (Langeler et al., 1993) whereas PC-3 cells represents 
androgen-independent, late stage cancer with high invasion potential (Kaighn et 
al., 1979).  
Our earlier work with LNCaP and PC-3 has shown that both cell lines are 
able to survive low oxygen environment for 48h (Hara et al., 2006). Although 
there was no loss in cell viability, the hypoxic cells showed significantly reduced 
cell proliferation rate as compared to their normoxic counterparts. Recently, 
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chronic hypoxia was reported to decrease invasion potential of highly aggressive 
PC-3 cells (Ackerstaff et al., 2007). As chronic hypoxia is well reported to 
facilitate cancer aggressiveness, it is important to assess the responses to 
chronic hypoxia in the context of disease progression stage of the cancer cells. 
This knowledge is useful in developing stage-specific cancer therapeutic 
strategies.  
Development of aggressive malignant phenotype in hypoxia occurs by 
modulating various biochemical and physiological processes (Vaupel et al., 
1989). Among the various biological processes modulated in hypoxia, we are 
interested in choline uptake and phosphorylation as it is often associated with 
high cell proliferation and tumor aggressiveness (DeGrado et al., 2001; Katz-Brull 
et al., 2002; Ramirez de Molina et al., 2002). Choline uptake and phosphorylation 
in tumors can be easily monitored by imaging techniques like PET (Shinoura et 
al., 1997; DeGrado et al., 2001) thereby allowing non-invasive cancer diagnosis. 
Interestingly, both choline uptake and phosphorylation is decreased in hypoxic 
prostate cancer cells. In PC-3 and LNCaP cells after 4h of hypoxia (0% O2), PC-3 
showed 15% decrease in choline uptake, whereas LNCaP showed 28% 
decrease in choline uptake (Hara et al., 2006). My work covered in previous 
chapters and recent work with hypoxic prostate cancer and breast cancer cell 
line, MCF-7 (Elvidge et al., 2006; Hara et al., 2006; Ackerstaff et al., 2007) has 
shown that the reason for reduced choline uptake and phosphorylation is in part 
due to down-regulation of expression of choline kinase in hypoxia. Down-
regulation of choline phosphorylation could possibly represent a crucial survival 
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strategy for hypoxic cancer cells. Choline phosphorylation is ATP consuming. 
Cancer cells must survive hypoxic stress by prioritizing use of ATP in various 
ATP requiring processes in the cell (Vaupel et al., 1989). Thus, a reduction in 
choline kinase activity may have an ATP sparing effect in energy starved hypoxic 
cells. Although decreased choline phosphorylation may conserve energy, but its 
survival advantage of decrease choline kinase expression in terms of its effect on 
malignant phenotypes of hypoxic cancer cells is at present not known. 
The goals of the present study were to 1) compare the effect of hypoxia on 
malignant phenotypes (cell proliferation, invasion and anchorage independent 
growth) in LNCaP and PC-3 prostate cancer cells and 2) assess how over-
expression of choline kinase in hypoxic prostate cancer cells affects their 
malignant phenotypes.  
Our results demonstrate that hypoxia affects malignant phenotype of 
prostate cancer cells depending on their disease progression stage. In terms of 
regulation of choline phosphorylation, it seems that reduced choline 
phosphorylation rate in late stage PC-3 cells is indeed a survival response to 
stressful hypoxic environment. Although, a mechanism to reduce choline 
phosphorylation exists in the early stage LNCaP cells, they are more tolerant to 
high choline kinase activity in hypoxic conditions than late stage PC-3 cells. 
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3. Materials and Methods 
3.1. Material 
ATCC, Manassas, VA 
PC-3 and LNCaP prostate cancer 
cells 
RPMI-1640 medium 
PBS 
Fetal bovine serum  
0.25% Trypsin-EDTA 
Eppendorf, Westbury, NY Centrifuge 5415R 
Sigma, St. Louis, MO 
Sodium Pentobarbital, Streptomycin, 
NaOH, SDS, RIPA lysis buffer, protease 
inhibitor cocktail, DMOG, chloroform, 
methanol, urea, sulfuric acid, acetonitrile, 
ammonium acetate, penicillin, scintillation 
cocktail, glacial acetic acid, HEPES , 
Triton X-100, EDTA, Bovine Adult Serum, 
N-tosyl-Lphenylalanine chloromethyl 
ketone (TPCK), trypsin inhibitor, 
leupeptin, DTT, PMSF), Tris, HCl, ATP, 
MgCl2, choline 
Waters, Milford, MA HPLC system 
Ruskinn Technologies, 
Bridgend, UK 
Invivo work station 
GE Healthcare (Amersham 
Biosciences), Piscataway, NJ  
[3H]choline 
 
3.2. Over-expression of choline kinase 
Cells were cultured in RPMI medium supplemented with 10% (v/v) fetal 
bovine serum (ATCC), 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Cells 
were grown at 37°C in a humidified incubator with a gas phase of 5% CO2. The 
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cells lines were transduced with the retrovirus (pHAGE-CMV-CHKA-ZsGreen-W) 
or control retrovirus (pHAGE-CMV-MCS-ZsGreen-W) containing medium mixed 
with 8 µg/ml Polybrene (SIGMA). The retroviruses were created by Dr. Jeng-Shin 
Lee, Dana-Farber / Harvard Cancer Center. 
3.3. Measurement of population doubling time  
Cells were trypsinized and suspended in a known volume of medium. The 
cell suspension was diluted 1000 fold with balanced electrolyte solution. Cells 
were counted in the diluted suspension using a particle counter. Doubling time 
was calculated using the formula DT (days) = T x 0.693 / ln (Nf / Ni), where DT is 
time needed to double a cell population, T is the incubation time in days, Ni is the 
cell number at the beginning of the incubation time and Nf is the cell number at 
the end of the incubation time.  
3.4. Colony formation assay 
Cells (0.5 104) were mixed with 1 ml of RPMI 1640 medium containing 
0.7% low melting agarose and 10% FBS and then plated on the bottom layer 
containing RPMI 1640 medium, and 0.8% low melting agarose with 10% FBS in 
each well of a six-well plate. The top agarose layer was overlaid with 1ml 
RPMI1640 medium with 10% FBS. The overlay medium was changed every 2 
days. After cultured for 21 days in normoxia (21% O2) or hypoxia (1% O2), 
colonies were counted after staining with 0.005% crystal violet.  
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3.5. Cell invasion assay 
Migration/Invasion assay was performed using BioCoat Tumor Invasion 
Systems (BD Bioscienes) according to manufacturer’s protocol. Invasion assay 
involved BD Falcon HTS FluoroBlok 24-Multiwell Insert System (8 μm) with BD 
Matrigel Matrix. Migration assay involved uncoated HTS FluoroBlok 24-Multiwell 
Insert System (8 μm) without BD Matrigel Matrix. PC-3 and LNCaP cells were 
grown in RPMI 1640 medium supplemented with 10% FBS. Cell suspensions 
were prepared by trypsinizing the monolayer and resuspending in RPMI 1640 
without FBS at 1 x 105 cells/ml. The insert plates were prepared by rehydrating 
the BD Matrigel™ Matrix coating with phosphate buffered saline for two hours at 
37°C. The rehydration solution was carefully removed, 0.75 ml RPMI-1640 
containing chemoattractant (10% FBS) was added to the plate well, and 0.5 ml of 
cell suspension (5 x 104) was added to each insert well. Uncoated insert plates, 
included as migration controls, were used without rehydration. This setup was 
incubated for 48 hours in normoxia (21% O2) or hypoxia (1% O2). Following 
incubation, the medium was removed from upper chamber and entire insert plate 
was transferred to a second 24-well plate containing 0.5 ml/well of 4 μg/ml 
Calcein AM (SIGMA) in Hanks buffered saline (SIGMA). The plates were 
incubated for one hour at 37°C and read in a fluorescence plate reader at 
excitation wavelength (ex) of 485 nm and emission wavelength (em) of 530 nm 
without further manipulation. Only labeled cells that pass through the BD Matrigel 
Matrix layer and the membrane were detected by fluorescence. 
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3.6. Statistical analysis  
Student’s t-test was applied for statistical evaluation and a P-value <0.05 
was considered significant. Results are presented as means ± standard deviation. 
4. Results 
4.1 Effect of over-expression of choline kinase on choline uptake 
Cells over-expressing choline kinase, PC-3 hChKα+ and LNCaP hChKα+ 
showed the expected increase in choline uptake as compared to PC-3 and 
LNCaP cells due to increased trapping of choline as phosphocholine (Figure 26). 
 
 
Figure 26. Effect of over-expression of hChKα on choline uptake in prostate 
cancer cells. # p < 0.05 Vs values in control cells not over-expressing hChKα 
using unpaired t-test. 
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4.2. Effect of over-expression of choline kinase and hypoxia on population 
doubling time 
Over-expression of choline kinase slightly increased population doubling 
time of normoxic PC-3 cells but caused a non-significant decrease in population 
doubling time of normoxic LNCaP cells (Figure 27). Hypoxia caused a decrease 
in cellular proliferation in all cases except for LNCaP hChKα+ cells. Decrease was 
more pronounced in PC-3 hChKα+ cells than other cells. 
 
 
Figure 27. Effect of hypoxia (1% O2, 24h) and over-expression of hChkα on 
cell population doubling time of prostate cancer cells. * p<0.05 values of 
hypoxia versus normoxia 
  
4.3. Effect of over-expression of choline kinase on cancer cell morphology  
PC-3 cells are strongly adherent cell line that grows as confluent layer of 
cells with no empty space between the cells whereas LNCaP cells are loosely 
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adherent cell line growing in clusters with lot of empty space between the 
clusters. LNCaP cells are more elongated than PC-3 cells. Over-expression of 
choline kinase had a pronounced effect on cell morphology and growth pattern of 
prostate cancer cells (Figure 28). Although cell shape and growth pattern of PC-3 
hChKα+ cells was not so different from parent PC-3 cells, LNCaP hChKα+ were 
more like PC-3 cells in shape and growth pattern as compared to parent LNCaP 
cells. LNCaP hChKα+ were not as elongated as parent LNCaP cells and were 
more like PC-3 cells. Like PC-3 cells, LNCaP hChKα+ grew as confluent layer of 
cells as opposed to parent LNCaP cells that grew in clusters. 
 
Figure 28. Effect of over-expression of hChKα on cell morphology of 
prostate cancer cells.  
 
4.4. Effect of over-expression of choline kinase and hypoxia on anchorage 
independent growth 
In this assay, the cells exhibiting anchorage independent growth form 
colonies in soft agar medium. LNCaP cells have typically a higher proliferation 
rate than PC-3 cells. This influenced the colony formation assay where LNCaP 
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was able to form more prominent colonies than PC-3 cells in semi-solid agar 
medium. Over-expression of choline kinase significantly increased the ability of 
LNCaP cells to grow in soft agar which was evident from the significant increase 
of colony forming units of LNCaP hChKα+ cells versus parent LNCaP cells 
(Figure 29). Hypoxia significantly decreased the number and size of colony 
forming units of LNCaP and LNCaP hChKα+ cells (Figure 29).  
 
Figure 29. Effect of over-expression of hChKα on anchorage independent 
growth of LNCaP prostate cancer cells.  
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4.5. Effect of over-expression of choline kinase and hypoxia on invasion 
potential of prostate cancer cells  
Hypoxia had a positive effect on invasion potential of prostate cancer cells 
(Figure 30). In the present study, PC-3 cells showed a modest increase in 
invasion potential in hypoxia (1% O2) whereas LNCaP cells showed a 9-fold 
increase in invasion potential in response to hypoxia. In late stage, PC-3 prostate 
cancer cells, over-expression of choline kinase caused a modest decrease in cell 
invasion potential in both normoxia and hypoxia. Whereas in early stage, LNCaP 
prostate cancer cells, over-expression of choline kinase dramatically increased 
invasion potential. In normoxia, over-expression of choline kinase resulted in 
transformation of LNCaP from a non-invasive cell line to a moderately invasive 
cell line. (Figure 30) The 25-fold increase in invasion was more than the one 
caused due to hypoxia. In PC-3 hChKα+ and LNCaP hChKα+ cells, hypoxia did 
not significantly increase the invasion potential, although an increasing trend was 
observed. 
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Figure 30. Effect of hypoxia and over-expression of hChKα on invasion 
potential of PC-3 and LNCaP prostate cancer cells. *p<0.05 values for 
hypoxia Vs normoxia and # p<0.05 values for PC-3 (hChKα+) and 
LNCaP(hChKα+) Vs PC-3 and LNCaP.  
 
4.6. Effect of over-expression of choline kinase and hypoxia on expression 
of pro-invasion factor, urokinase plasminogen activator (uPa)  
The expression pattern of uPA correlated with the invasion pattern of 
prostate cancer cells in response to over-expression of choline kinase and 
hypoxia (Figure 31). Upon hypoxic exposure there was significant increase in 
uPA expression in LNCaP but no significant difference was observed between 
normoxic and hypoxic PC-3 cells (data not shown). In LNCaP cells, over-
expression of choline kinase increased uPA expression in normoxia and this 
increased uPA expression was also maintained in hypoxia. 
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Figure 31. Effect of hypoxia and over-expression of hChKα on expression 
of promigratory factor, uPA in LNCaP prostate cancer cells. * p < 0.05 Vs 
values in normoxia using unpaired t-test. Relative expression represents 
expression normalized to expression in normoxic LNCaP cells. 
 
5. Discussion 
Decreased choline phosphorylation and down-regulation of choline kinase 
in hypoxic cancer cells is well reported but its survival advantage in terms of its 
effect on malignant phenotypes of hypoxic cancer cells is at present not known. 
In our study we addressed this issue by generating stable prostate cancer cell 
lines of LNCaP and PC-3 cells that over-express choline kinase independent of 
normoxic and hypoxic conditions. This allowed us to examine the relationship of 
malignant phenotypes to choline kinase expression and hypoxia in the two 
prostate cancer cell lines.  
The original hypothesis of this study was that over-expression of choline 
kinase will have a positive effect on proliferation rate of cancer cells. This was 
89 
 
based on the fact that over-expression of choline kinase is often associated with 
malignancy and high proliferation. Recently, correlation studies have shown that 
hypoxia and increased choline kinase activity exist together in tumors (Glunde et 
al, 2008). It was proposed that together they should be promoting malignancy. 
However the data obtained in the present study showed that response to over-
expression of choline kinase and hypoxia depends on the disease stage of 
cancer. Over-expression of choline kinase was not favored by late stage 
representing PC-3 prostate cancer cells as it caused a decrease in cellular 
proliferation which was more significant in hypoxia. On the other hand, LNCaP 
cells that represent early stage prostate cancer responded favorably to increased 
choline kinase activity as seen from increases in cellular proliferation. Over-
expression of choline kinase also enhanced anchorage independent growth of 
LNCaP cells, whereas hypoxia significantly decreased the size of the colonies 
probably due to decrease in proliferation rate. In late stage PC-3 cells, hypoxia 
together with increased choline kinase activity profoundly decreased cellular 
proliferation.  
Hypoxia and choline kinase not only modulate proliferation rate of cancer 
cells but also influence their invasion potential. Hypoxia had a positive effect on 
invasion potential of PC-3 and LNCaP prostate cancer cells consistent with 
earlier reports that showed increased invasion upon hypoxic exposure in breast 
cancer cell lines, MDA-MB-231 and MDA-MB-435 (Graham et al., 1999) and 
colon cancer cell line, HCT116 (Krishnamachary et al., 2003). In the present 
study, PC-3 prostate cancer cell line showed a modest increase in invasion 
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potential in hypoxia (1% O2) whereas LNCaP prostate cancer cells showed a 
more pronounced response to hypoxia. LNCaP cells were non-invasive in 
normoxic condition but hypoxia caused LNCaP to attain invasive characteristic. 
In this regard, our results contradict an earlier study where hypoxia decreased 
cell invasion of PC-3 cells in as low as 12h of exposure (Ackerstaff et al., 2007). 
The reason for this disagreement is not clear but there were methodological 
differences in performance of the invasion assay. In general, cell invasion assays 
employ two chambers separated by a reconstituted basement membrane 
(matrigel). There are two essential requirements for this assay, 1) directed cell 
movement from upper chamber to lower chamber through the matrigel and 2) 
degradation of matrigel barrier by invading cells. Ours and other studies (Graham 
et al., 1999; Krishnamachary et al., 2003) that showed a positive effect of 
hypoxia on cell invasion followed the widely used serum gradient directed cell 
movement in the invasion assay. In this methodology, the upper chamber 
contains cancer cells in serum free medium and lower chamber contains medium 
with 10% serum. The serum in the lower chamber acts as chemoattractant 
promoting directed movement of cells from upper chamber to lower 
chamber. This methodology closely mimics the in vivo conditions where chemo-
attractant based gradients between primary tumors, circulating blood and 
metastatic sites are important factors that contribute to cellular invasion (Moore 
et al., 2001). The contradicting report employed a perfusion based cell invasion 
system in which cell movement was directed not by a serum gradient but by the 
flow of perfused medium which was from the upperchamber to the lower 
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chamber (Ackerstaff et al., 2007). Serum is an important factor in invasion 
assays. This is evident from studies with choriocarcinoma HTR-8/SVneo cells 
performed in the absence of serum showed a negative effect of hypoxia on 
invasion potential of these cells (Kilburn et al., 2000) but in a different study, the 
invasion potential of HTR-8/SVneo cells was significantly increased by hypoxia in 
the presence of a serum gradient (Graham et al., 1998). Similar differences in 
invasion response to hypoxia due to serum gradient were reported in the breast 
cancer cell line MDA-MB-231 (Munoz-Najar et al., 2006). Finally, another 
methodological difference in the contradicting report is that their calculated 
invasion potential (invasion index) reflected both cell migration and matrigel 
physical degradation caused by invading cells. This differed from the invasion 
index that I measured which reflected only cell invasion. 
Promigratory factor, uPA is a serine protease that converts plasminogen 
into plasmin, a broadly acting protease that degrades several extracellular matrix 
proteins. Consistent with its role in cancer progression, multiple groups have 
shown that high levels of uPA in primary breast cancers are independently 
associated with metastasis (Foekens et al., 1992). uPA level indicates invasion 
potential of prostate cancer cell line evident from high uPA levels in highly 
invasive, PC-3 cells and absence of uPA in non-invasive LNCaP cells (Pentyala 
et al., 1998). In the case of PC-3 prostate cancer cells, PC-3 transfected with a 
mutant inactive form of uPA, displayed reduced metastatic ability when 
inoculated into nude mice, suggesting involvement of uPA in cell invasiveness 
(Crowley et al., 1993). In present study, the expression pattern of uPA correlated 
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with the invasion pattern seen in hypoxic prostate cancer cells. Hypoxia and 
over-expression of choline kinase caused significant increase in uPA expression 
in LNCaP but no significant difference was observed in PC-3 cells. These 
observations suggest that hypoxia and choline kinase affects these two prostate 
cancer cell lines in different ways in terms of modulating cell uPA expression. It is 
possible that the highly invasive PC-3 cells have little room for further increase in 
invasion potential while the relatively non-invasive LNCaP cells have more 
potential of being modulated. Cells that are noninvasive can be become invasive 
with changes in microenvironment. Our present work provides first evidence that 
hypoxia and ChKα expression could be affecting malignant phenotypes of 
prostate cancer cells depending on their stage in cancer disease progression. 
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CONCLUSIONS 
 
Present work clarifies the status of choline metabolism and regulation of 
choline kinase expression in hypoxic cancer cells. In addition it presents 
preliminary results showing that inhibition of choline kinase in hypoxic cancer 
cells might have a survival advantage depending on disease stage of cancer. In 
the cancer cells that were studied, 9L glioma cells, PC-3 and LNCaP prostate 
cancer cells, it was observed that hypoxia universally inhibits choline uptake 
/phosphorylation in all cancer cells independent of their origin. Inhibition of 
choline phosphorylation was strong in some cells (PC-3) and modest in others 
(9L glioma and LNCaP). Response in cultured cancer cells were further 
confirmed when inhibition of choline phosphorylation was also seen in hypoxic 9L 
tumor animal model. Decreased choline phosphorylation resulted in transient 
uptake of choline radiotracers in cultured cancer cells and 9L tumors suggesting 
potential problem in using choline as a biomarker for cancers in hypoxic 
microenvironment.  
To investigate the mechanism behind decrease in choline phosphorylation, 
steady state levels of choline metabolites were measured and choline kinase 
catalyzed choline phosphorylation step was found to be rate-limiting in PC-3 cells. 
This suggested that modulation in choline kinase levels can alter choline 
metabolism in hypoxic cancer cells. Expression and activity assays for choline 
kinase revealed that choline kinase expression is down-regulated in hypoxia. 
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This regulation involved transcriptional level mediation by HIF1 at the conserved 
HRE7 site in choline kinase promoter.  
The mechanism behind this HIF-1 mediated response and reason for 
inhibition of choline kinase in hypoxic cells is not known but preliminary 
experiments suggest that this inhibition might have a survival advantage to 
cancer cells depending on their stage in cancer disease progression. Over-
expression of choline kinase in hypoxic PC-3 cells was not well tolerated in our 
study as it resulted in significant reduction in invasion potential and slower 
population doubling rate. Further study showed that in contrast to highly invasive 
PC-3, in non-invasive LNCaP cells, over-expression of choline kinase was 
tolerated in hypoxia. Over-expression of choline kinase significantly increased 
invasion potential of LNCaP cells with no significant difference in population 
doubling time. These results suggests that tumor microenvironment are important 
for progression of early-stage, androgen-dependent LNCaP prostate cancer cells 
but confer little survival advantage in undifferentiated, androgen-independent PC-
3 prostate cancer cells. 
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